

FOR OFFICIAL USE ONLY

ACCESS DB # 301072

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

MICHAEL P. WOODWARD
SUPERVISORY PATENT EXAMINER

SEARCH REQUEST FORM

Requester: Pryor Examiner #: 74458 Date: 9/7/06
Art Unit: 1616 Phone Number: 2-0621 Serial Number: 10/797,927
Location (Bldg/Room#): 4REM39 (Mailbox #): 4REM70 Results Format Preferred (circle): PAPER DISK


To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Melanin-concentrating hormone receptor-antagonist
Inventors (please provide full names): Val Goodfellow; Martin Rowbottom;
Brian Dyck; Junko Tamiya; Mingzhu Zhang; Jonathan Gre;
Troy Vickers
Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations; authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



$R_4 = \text{alkyl, aryl, heterocycle, } NR_7R_8$

$R_7 \text{ or } R_8 = \text{H, Alkyl, Aryl, heterocycle (or)}$

taken together w/ "N" to form
a heterocyclic ring

$m = 0 \text{ @ } 1$

$n = 1 \text{ @ } 2$

$X = -CH_2- \text{ or } -N(R_6)-$

$R_6 = \text{H, Alkyl}$

* See claim 1 attached



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 201072

TO: Alton Pryor
Location: REM/4A39/4C70
Art Unit: 1616
September 8, 2006 ←

Case Serial Number: 10/797927

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

=> d his ful

(FILE 'HOME' ENTERED AT 17:00:34 ON 08 SEP 2006)

FILE 'REGISTRY' ENTERED AT 17:01:26 ON 08 SEP 2006

L1 STR
L2 34 SEA SSS SAM L1
L3 857 SEA SSS FUL L1

FILE 'HCAPLUS' ENTERED AT 17:07:43 ON 08 SEP 2006

L4 4 SEA ABB=ON PLU=ON L3
D STAT QUE L4
D IBIB ABS HITSTR L4 1-4
SELECT HIT RN 1-4

FILE 'REGISTRY' ENTERED AT 17:13:32 ON 08 SEP 2006

L6 835 SEA ABB=ON PLU=ON (762279-00-5/BI OR 762279-90-3/BI OR
762279-95-8/BI OR 762280-16-0/BI OR 762280-19-3/BI OR 762280-21
-7/BI OR 762280-70-6/BI OR 762280-87-5/BI OR 762280-95-5/BI OR
762281-98-1/BI OR 762281-99-2/BI OR 762282-05-3/BI OR 762282-27
-9/BI OR 762282-28-0/BI OR 762282-50-8/BI OR 762282-79-1/BI OR
762282-98-4/BI OR 762283-00-1/BI OR 762283-25-0/BI OR 762283-27
-2/BI OR 762283-40-9/BI OR 762284-08-2/BI OR 762284-09-3/BI OR
762284-12-8/BI OR 762284-13-9/BI OR 762284-16-2/BI OR 762284-18
-4/BI OR 762284-21-9/BI OR 762284-22-0/BI OR 762284-31-1/BI OR
762284-33-3/BI OR 762284-35-5/BI OR 762284-36-6/BI OR 762284-37
-7/BI OR 762284-40-2/BI OR 762284-41-3/BI OR 762284-43-5/BI OR
762284-44-6/BI OR 762284-46-8/BI OR 762284-47-9/BI OR 762284-48
-0/BI OR 762284-49-1/BI OR 762284-50-4/BI OR 762284-56-0/BI OR
762284-57-1/BI OR 762284-61-7/BI OR 762284-68-4/BI OR 762284-70
-8/BI OR 762285-98-3/BI OR 762285-99-4/BI OR 762286-00-0/BI OR
762286-23-7/BI OR 380221-82-9/BI OR 762277-55-4/BI OR 762277-56
-5/BI OR 762277-57-6/BI OR 762277-59-8/BI OR 762277-61-2/BI OR
762277-63-4/BI OR 762277-66-7/BI OR 762277-69-0/BI OR 762277-71
-4/BI OR 762277-73-6/BI OR 762277-74-7/BI OR 762277-75-8/BI OR
762277-76-9/BI OR 762277-77-0/BI OR 762277-78-1/BI OR 762277-79
-2/BI OR 762277-80-5/BI OR 762277-81-6/BI OR 762277-82-7/BI OR
762277-83-8/BI OR 762277-84-9/BI OR 762277-85-0/BI OR 762277-86
-1/BI OR 762277-87-2/BI OR 762277-88-3/BI OR 762277-89-4/BI OR
762277-90-7/BI OR 762277-91-8/BI OR 762277-92-9/BI OR 762277-93
-0/BI OR 762277-94-1/BI OR 762277-95-2/BI OR 762277-97-4/BI OR
762277-98-5/BI OR 762277-99-6/BI OR 762278-00-2/BI OR 762278-01
-3/BI OR 762278-02-4/BI OR 762278-03-5/BI OR 762278-04-6/BI OR
762278-06-8/BI OR 762278-08-0/BI OR 762278-10-4/BI OR 762278-12
-6/BI OR 762278-14-8/BI OR 762278-16-0/BI OR 762
L7 22 SEA ABB=ON PLU=ON L3 NOT L6
D IDE CAN L7 1-22

FILE 'REGISTRY' ENTERED AT 17:17:06 ON 08 SEP 2006

L10 STR L1
L11 915 SEA SSS FUL L10
L12 58 SEA ABB=ON PLU=ON L11 NOT L3

FILE 'HCAPLUS' ENTERED AT 17:19:17 ON 08 SEP 2006

L13 22 SEA ABB=ON PLU=ON L12
L14 22 SEA ABB=ON PLU=ON L13 NOT L4
D STAT QUE L14
D IBIB ABS HITSTR L14 1-22
L15 47 SEA ABB=ON PLU=ON ("GOODFELLOW V"/AU OR "GOODFELLOW V J"/AU
OR "GOODFELLOW V S"/AU OR "GOODFELLOW VAL"/AU OR "GOODFELLOW

THIS PAGE BLANK (USPTO)


```

VAL S"/AU OR "GOODFELLOW VAL SMITH"/AU OR "GOODFELLOW VALERIE"/
AU OR "GOODFELLOW VALERIE J"/AU)
L16      22 SEA ABB=ON PLU=ON ("ROWBOTTOM MARTIN"/AU OR "ROWBOTTOM
MARTIN W"/AU)
L17      35 SEA ABB=ON PLU=ON "DYCK B"/AU OR ("DYCK BRIAN"/AU OR "DYCK
BRIAN P"/AU OR "DYCK BRIAN PETER"/AU)
L18      14 SEA ABB=ON PLU=ON "TAMIYA JUNKO"/AU
L19      432 SEA ABB=ON PLU=ON ZHANG M ?/AU OR "ZHANG MINGZHU"/AU
L20      35 SEA ABB=ON PLU=ON GREY J- ?/AU OR "GREY JONATHAN"/AU
L21      12 SEA ABB=ON PLU=ON "VICKERS T"/AU OR ("VICKERS TROY"/AU OR
"VICKERS TROY D"/AU)
L22      7 SEA ABB=ON PLU=ON L15 AND L16 AND L17 AND L18 AND L19 AND
L20 AND L21
L23      16 SEA ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR L19 OR L20
OR L21)
L24      9 SEA ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19 OR L20 OR L21)
L25      10 SEA ABB=ON PLU=ON L17 AND (L18 OR L19 OR L20 OR L21)
L26      8 SEA ABB=ON PLU=ON L18 AND (L19 OR L20 OR L21)
L27      7 SEA ABB=ON PLU=ON L19 AND (L20 OR L21)
L28      7 SEA ABB=ON PLU=ON L20 AND L21
L29      14 SEA ABB=ON PLU=ON (L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
L28) NOT (L4 OR L14)
D STAT QUE L29
D IBIB ABS L29 1-14

```

```

FILE 'REGISTRY' ENTERED AT 17:39:47 ON 08 SEP 2006
L30      436 SEA ABB=ON PLU=ON MELANIN

```

```

FILE 'HCAPLUS' ENTERED AT 17:40:08 ON 08 SEP 2006
L31      11785 SEA ABB=ON PLU=ON L30 OR MELANIN
L32      8 SEA ABB=ON PLU=ON ((L22 OR L23 OR L24 OR L25 OR L26 OR L27
OR L28) AND L31) NOT (L4 OR L14)
D STAT QUE L32
D IBIB ABS L32 1-8

```

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2006 HIGHEST RN 906063-52-3
 DICTIONARY FILE UPDATES: 7 SEP 2006 HIGHEST RN 906063-52-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCAPLUS

THIS PAGE BLANK (USPTO)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 7 Sep 2006 (20060907/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

THIS PAGE BLANK (USPTO)

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 17:07:43 ON 08 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


```
FILE COVERS 1907 - 8 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 7 Sep 2006 (20060907/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=>
=>
```

```
=> d stat que l4
L1 STR
```



```
VAR G1=AK/CY/18
VAR G2=CH2/N
REP G3=(1-2) CH2
REP G4=(0-1) CH2
NODE ATTRIBUTES:
NSPEC IS RC AT 18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18
```

```
STEREO ATTRIBUTES: NONE
L3 857 SEA FILE=REGISTRY SSS FUL L1
L4 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L3
```

=>
=>

=> d ibib abs hitstr l4 1-4

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:544608 HCAPLUS

DOCUMENT NUMBER: 143:229673

TITLE: Synthesis and structure-activity relationships of biarylcarboxamide bis-aminopyrrolidine urea derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1)

AUTHOR(S): Rowbottom, Martin W.; Vickers, Troy D.; Dyck, Brian; Tamiya, Junko; Zhang, Mingzhu; Zhao, Liren; Grey, Jonathan; Provencal, David; Schwarz, David; Heise, Christopher E.; Mistry, Monica; Fisher, Andrew; Dong, Teresa; Hu, Tao; Saunders, John; Goodfellow, Val S.

CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences Inc., San Diego, CA, 92130, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(14), 3439-3445

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:229673

AB A novel series of bis-aminopyrrolidine ureas containing either a 4-biphenylcarboxamide or 5-phenyl-2-thiophenecarboxamide group have been identified as potent and functional antagonists of the melanin-concentrating hormone receptor-1. Syntheses and SAR are described, which led to the discovery of compds. with high binding affinity ($K_i = 1$ nM) for the receptor. Preliminary in vitro metabolic stability data are also reported for key compds.


IT 762286-23-7P 862847-08-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biarylcarboxamide bis-aminopyrrolidine urea-derived small-mol. antagonists of melanin-concentrating hormone receptor-1 (MCH-R1) and study of their structure-activity relationship)

RN 762286-23-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(5-bromo-2-thienyl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidiny]-], (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862847-08-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-iodobenzoyl)methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 762282-27-9P 762284-68-4P 762284-70-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of chiral [[(biphenyl)carbonyl]amino]-N-[(methyl)pyrrolidinyl]pyrrolidinecarboxamide and study of its activity as antagonist of melanin-concentrating hormone receptor-1 (MCH-R1) and study of its structure-activity relationship)

RN 762282-27-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl)carbonyl)methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-68-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-methoxy[1,1'-biphenyl]-4-yl)carbonyl)methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-70-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-methoxy-2'-methyl[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 762282-28-0P 762283-40-9P 762284-08-2P
 762284-09-3P 762284-12-8P 762284-13-9P
 762284-16-2P 762284-18-4P 762284-21-9P
 762284-22-0P 762284-31-1P 762284-33-3P
 762284-35-5P 762284-36-6P 762284-37-7P
 762284-40-2P 762284-41-3P 762284-43-5P
 762284-44-6P 762284-46-8P 762284-47-9P
 762284-48-0P 762284-49-1P 762284-50-4P
 762284-56-0P 762284-57-1P 762284-61-7P
 862847-09-4P 862847-10-7P 862847-11-8P
 862847-12-9P 862847-13-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of chiral [[[aryl]thienyl]carbonyl]amino]-N-[(methyl)pyrrolidinyl]pyrrolidinecarboxamide and study of its activity as antagonist of melanin-concentrating hormone receptor-1 (MCH-R1) and study of its structure-activity relationship)

RN 762282-28-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-40-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-08-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chloro-4-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-09-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chloro-2-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-12-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(methylsulfonyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762284-13-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-dichlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-16-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[2-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-18-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(1-methylethoxy)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762284-21-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[3-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-22-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chloro-4-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI)

(3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-31-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-33-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxy-2-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-35-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidiny]-3-
 [methyl[[5-[4-(trifluoromethoxy)phenyl]-2-thienyl]carbonyl]amino]-, (3S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-36-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-ethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidiny]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762284-37-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-cyanophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidiny]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-40-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-(2-methylphenyl)-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762284-41-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-(4-methylphenyl)-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 762284-43-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI)

(3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-44-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-46-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,6-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-47-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-48-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-49-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-50-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-chlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-56-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(1-methylethyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 762284-57-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-[4-(dimethylamino)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, CN(C)C1CCN1CNC(=O)c2cc3cc(C4=CC=C(C=C4)N(C)C)ccc3s2

(3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-61-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862847-09-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3S)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862847-10-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3S)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862847-11-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862847-12-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-hydroxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862847-13-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:86407 HCAPLUS

DOCUMENT NUMBER: 142:336202

TITLE: Bis(aminopyrrolidine)-derived ureas (APUs) as potent MCH1 receptor antagonists

AUTHOR(S): Grey, Jonathan; Dyck, Brian; Rowbottom, Martin W.; Tamiya, Junko; Vickers, Troy D.; Zhang, Mingzhu; Zhao, Liren; Heise, Christopher E.; Schwarz, David; Saunders, John; Goodfellow, Val S.

CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92130, USA


SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 999-1004

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:336202
GI



AB Ureas, e.g., I, derived from two substituted 3-aminopyrrolidine subunits were prepared as constrained analogs of a linear lead compound and tested as antagonists of the MCH1 receptor. The series was optimized for substitution and stereochem. to generate a functional antagonist with a K_i of 3.3 nM and IC_{50} of 12 nM (GTP γ S).

IT 762279-00-5P 762279-90-3P 762279-95-8P
762280-16-0P 762280-19-3P 762280-21-7P
762280-70-6P 762280-87-5P 762280-95-5P
762281-32-3P 762281-98-1P 762281-99-2P
762282-05-3P 762282-50-8P 762282-79-1P
762282-98-4P 762283-00-1P 762283-25-0P
762283-27-2P 762285-99-4P 762286-00-0P
794479-71-3P 848464-85-7P 848464-87-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and MCH1 receptor binding affinity of bis(aminopyrrolidine)-derived ureas starting from aminopyrrolidines, aldehydes, ketones, and acid chlorides)

RN 762279-00-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylamino)carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-90-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonylamino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-95-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-[(4-chlorophenyl)sulfonyl]ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonylamino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762280-16-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(1-methyl-4-piperidinyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762280-19-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-chlorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762280-21-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Prvcr 10_737327

pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-70-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-87-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-butyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-95-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-

pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-32-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(1-pyrrolidinylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-98-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-99-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Bu-t

RN 762282-05-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[5-(4-chlorophenyl)-1,5-dioxopentyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-50-8 HCAPLUS

CN 5-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-79-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[4-(6-methoxy-3-pyridazinyl)benzoyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-98-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3S)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-00-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-25-0 HCAPLUS

CN 1H-Imidazole-4-carboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-27-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762285-99-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 762286-00-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-hydroxyethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 794479-71-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 848464-85-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 848464-87-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3S)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 762285-98-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and MCH1 receptor binding affinity of bis(aminopyrrolidine)-


Prvcr: 10.79/857

derived ureas starting from aminopyrrolidines, aldehydes, ketones, and acid chlorides)

RN 762285-98-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:780696 HCAPLUS

DOCUMENT NUMBER: 141:295849

TITLE: Preparation of carboxamidopyrrolidines as melanin-concentrating hormone receptor antagonists and compositions and methods related thereto

INVENTOR(S): Goodfellow, Val; Rowbottom, Martin; Dyck, Brian P.; Tamiya, Junko; Zhang, Mingzhu; Grey, Jonathan; Vickers, Troy D.

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 180 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081005	A1	20040923	WO 2004-US7259	20040308
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2006178403 A1 20060810 US 2004-797927 20040308

PRIORITY APPLN. INFO.: US 2003-452776P P 20030307

US 2003-518265P P 20031107

OTHER SOURCE(S): MARPAT 141:295849

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [m = 0 or 1; n = 1 or 2; X = -CH₂-, or -N(R₆)-; R₁ = H, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R₂ and R₅ independently = H, (un)substituted alkyl; R₃ = H, (un)substituted-alkyl, -arylalkyl, -heteroarylalkyl; R₄ = (un)substituted-alkyl, -aryl, -heterocycle; R₆ = H or (un)substituted alkyl] and their pharmaceutically acceptable salt, are disclosed as melanin-concentrating hormone (MCH) receptor antagonists having utility for the treatment of MCH receptor-based disorders such as obesity. Thus, e.g., II was prepared via amidation of of III (preparation given) with benzoyl chloride. Methods for evaluation of compds. are described (no data). Also disclosed are compns. containing a compound of this invention, as well as methods relating to the use thereof.

IT 762279-42-5P 762282-71-3P 762285-34-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of carboxamidopyrrolidine derivs. as melanin-concentrating hormone receptor antagonists)

RN 762279-42-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-71-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4'-yl]carbonyl]amino]-N-[(3R)-1-(4-oxocyclohexyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762285-34-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl([1,1':4',1''-terphenyl]-4-ylcarbonyl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 762277-55-4P 762277-56-5P 762277-57-6P
 762277-59-8P 762277-61-2P 762277-63-4P
 762277-66-7P 762277-69-0P 762277-71-4P
 762277-73-6P 762277-74-7P 762277-75-8P
 762277-76-9P 762277-77-0P 762277-78-1P
 762277-79-2P 762277-80-5P 762277-81-6P
 762277-82-7P 762277-83-8P 762277-84-9P
 762277-85-0P 762277-86-1P 762277-87-2P
 762277-88-3P 762277-89-4P 762277-90-7P
 762277-91-8P 762277-92-9P 762277-93-0P
 762277-94-1P 762277-95-2P 762277-97-4P
 762277-98-5P 762277-99-6P 762278-00-2P
 762278-01-3P 762278-02-4P 762278-03-5P
 762278-04-6P 762278-06-8P 762278-08-0P
 762278-10-4P 762278-12-6P 762278-14-8P
 762278-16-0P 762278-18-2P 762278-20-6P
 762278-22-8P 762278-24-0P 762278-25-1P

762278-26-2P 762278-28-4P 762278-29-5P
 762278-30-8P 762278-31-9P 762278-32-0P
 762278-33-1P 762278-34-2P 762278-35-3P
 762278-36-4P 762278-37-5P 762278-38-6P
 762278-39-7P 762278-40-0P 762278-41-1P
 762278-42-2P 762278-43-3P 762278-44-4P
 762278-45-5P 762278-46-6P 762278-47-7P
 762278-48-8P 762278-49-9P 762278-50-2P
 762278-51-3P 762278-52-4P 762278-53-5P
 762278-54-6P 762278-55-7P 762278-56-8P
 762278-57-9P 762278-58-0P 762278-59-1P
 762278-60-4P 762278-61-5P 762278-62-6P
 762278-63-7P 762278-64-8P 762278-65-9P
 762278-66-0P 762278-67-1P 762278-68-2P
 762278-69-3P 762278-70-6P 762278-71-7P
 762278-72-8P 762278-73-9P 762278-74-0P
 762278-75-1P 762278-76-2P 762278-77-3P
 762278-78-4P 762278-79-5P 762278-80-8P
 762278-81-9P 762278-82-0P 762278-83-1P
 762278-84-2P 762278-85-3P 762278-86-4P
 762278-87-5P 762278-88-6P 762278-89-7P
 762278-90-0P 762278-91-1P 762278-92-2P
 762278-93-3P 762278-94-4P 762278-95-5P
 762278-96-6P 762278-97-7P 762278-98-8P
 762278-99-9P 762279-00-5P 762279-01-6P
 762279-02-7P 762279-03-8P 762279-04-9P
 762279-05-0P 762279-06-1P 762279-07-2P
 762279-08-3P 762279-09-4P 762279-10-7P
 762279-11-8P 762279-12-9P 762279-13-0P
 762279-14-1P 762279-15-2P 762279-16-3P
 762279-17-4P 762279-18-5P 762279-19-6P
 762279-20-9P 762279-21-0P 762279-22-1P
 762279-23-2P 762279-24-3P 762279-25-4P
 762279-26-5P 762279-27-6P 762279-28-7P
 762279-29-8P 762279-30-1P 762279-31-2P
 762279-32-3P 762279-33-4P 762279-34-5P
 762279-35-6P 762279-36-7P 762279-37-8P
 762279-38-9P 762279-39-0P 762279-40-3P
 762279-41-4P 762279-43-6P 762279-44-7P
 762279-45-8P 762279-46-9P 762279-47-0P
 762279-48-1P 762279-49-2P 762279-50-5P
 762279-51-6P 762279-52-7P 762279-53-8P
 762279-54-9P 762279-55-0P 762279-56-1P
 762279-57-2P 762279-58-3P 762279-59-4P
 762279-60-7P 762279-61-8P 762279-62-9P
 762279-63-0P 762279-64-1P 762279-65-2P
 762279-66-3P 762279-67-4P 762279-68-5P
 762279-69-6P 762279-70-9P 762279-71-0P
 762279-72-1P 762279-73-2P 762279-74-3P
 762279-75-4P 762279-76-5P 762279-77-6P
 762279-78-7P 762279-79-8P 762279-80-1P
 762279-81-2P 762279-82-3P 762279-83-4P
 762279-84-5P 762279-85-6P 762279-86-7P
 762279-87-8P 762279-88-9P 762279-89-0P
 762279-90-3P 762279-91-4P 762279-92-5P
 762279-93-6P 762279-94-7P 762279-95-8P
 762279-96-9P 762279-97-0P 762279-98-1P
 762279-99-2P 762280-00-2P 762280-01-3P
 762280-02-4P 762280-03-5P 762280-04-6P
 762280-05-7P 762280-06-8P 762280-07-9P

762280-08-0P 762280-09-1P 762280-10-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of carboxamidopyrrolidine derivs. as melanin-concentrating hormone receptor antagonists)

RN 762277-55-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[benzoyl[[4-(trifluoromethyl)phenyl]methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-56-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(3,4-dichlorobenzoyl)[[4-(trifluoromethyl)phenyl]methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-57-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]ethylamino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-59-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl](2-methylpropyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-61-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[(phenylmethyl)[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-63-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4-cyanophenyl)methyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-66-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3,4-dichlorophenyl)methyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-69-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[ethyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-71-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[(2-methylpropyl)[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-73-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(2,2-dimethylpropyl)[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-74-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl](phenylmethyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-75-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl][(4-cyanophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-76-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl]ethylamino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-77-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl](2-methylpropyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-78-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl](2,2-dimethylpropyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-79-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[benzoyl[(4-chlorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-80-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[benzoyl[(4-fluorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-81-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[benzoyl[(4-cyanophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-82-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[benzoyl[(3,4-dichlorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-83-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[benzoyl[(3,5-dichlorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-84-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[benzoyl(2-methylpropyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-85-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[benzoyl(2,2-dimethylpropyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-86-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4-chlorophenyl)methyl][4-(trifluoromethyl)benzoyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-87-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3,4-dichlorophenyl)methyl][4-(trifluoromethyl)benzoyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-88-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3,5-dichlorophenyl)methyl][4-(trifluoromethyl)benzoyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-89-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[(2-methylpropyl) [4-(trifluoromethyl)benzoyl]amino]-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-90-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(2,2-dimethylpropyl) [4-(trifluoromethyl)benzoyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-91-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(3,4-dichlorobenzoyl) [(3,4-dichlorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-92-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(3,4-dichlorobenzoyl) [(3,5-dichlorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-93-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(3,5-dichlorobenzoyl) [(3,4-dichlorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-94-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(3,5-dichlorobenzoyl)(2-methylpropyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-95-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(3,5-dichlorobenzoyl)(2,2-dimethylpropyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762277-97-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[([1,1'-biphenyl]-4-ylcarbonyl)amino]-N-methyl-N-[1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 762277-96-3

CMF C32 H38 N4 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 762277-98-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-N-methyl-N-[1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762277-99-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-methyl-N-[1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-00-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-methyl-N-[1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762278-01-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-methyl-N-[1-(3-phenylpropyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 762278-02-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl)methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-03-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 762278-04-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B




RN 762278-06-8 HCAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-[[1-(phenylmethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 762278-05-7
 CMF C31 H35 N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 762278-08-0 HCAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-[[1-(3-phenylpropyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 762278-07-9
 CMF C33 H39 N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 762278-10-4 HCAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-[(1-pentyl-3-pyrrolidinyl)acetyl]-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 762278-09-1
 CMF C29 H39 N3 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 762278-12-6 HCAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[(1-cyclohexyl-3-pyrrolidinyl)acetyl]-3-pyrrolidinyl]-N-methyl-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 762278-11-5

CMF C30 H39 N3 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 762278-14-8 HCAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[[1-(cyclopropylmethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-N-methyl-, mono(trifluoroacetate)
 (9CI) (CA INDEX NAME)

CM 1


CRN 762278-13-7
 CMF C28 H35 N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 762278-16-0 HCAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[[1-(2,2-diphenylethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-N-methyl-, mono(trifluoroacetate)
 (9CI) (CA INDEX NAME)

CM 1

CRN 762278-15-9
 CMF C38 H41 N3 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 762278-18-2 HCAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[[1-(cyclohexylmethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-N-methyl-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 762278-17-1

CMF C31 H41 N3 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 762278-20-6 HCAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[[1-(1-cyclohexylethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-N-methyl-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 762278-19-3

CMF C32 H43 N3 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 762278-22-8 HCAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-[(1-methyl-3-pyrrolidinyl)acetyl]-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 762278-21-7

CMF C25 H31 N3 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 762278-24-0 HCAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[(1-cyclobutyl-3-pyrrolidinyl)acetyl]-3-pyrrolidinyl]-N-methyl-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 762278-23-9

CMF C28 H35 N3 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 762278-25-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N,2-dimethyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-3-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-26-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclohexyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762278-28-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[(3'-fluoro-2',4'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 762278-27-3
 CMF C35 H43 F N4 O2

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 762278-29-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


pyol 10_797927



RN 762278-30-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[4-(3-thienyl)benzoyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-31-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-32-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-33-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2',4'-dimethoxy[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-34-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2'-[(dimethylamino)methyl][1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-35-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro-3-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-36-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[2-methyl-4-(3-thienyl)benzoyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-37-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3'-methoxy-3-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-38-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2'-methoxy-3-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-39-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2',4'-dimethoxy-3-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-40-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro-2-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-41-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[3-methyl-4-(3-thienyl)benzoyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-42-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3'-methoxy-2-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-43-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2'-methoxy-2-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-44-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2',4'-dimethoxy-2-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-45-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-(acetamino)-2-methyl[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762278-46-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[4'-ethoxy[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762278-47-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[(3'-cyano[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762278-48-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[(4'-cyano[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762278-49-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[5-[4-(hydroxymethyl)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-50-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[5-(4-cyanophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-51-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[5-(3-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762278-52-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-benzofuranyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762278-53-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[5-(6-methoxy-3-pyridinyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762278-54-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethoxy)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762278-55-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-benzofuranyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-56-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-benzo[b]thien-2-yl-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-57-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(3-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-58-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(3,5-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-59-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-benzofuranyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-60-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(3-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-61-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-[4-(hydroxymethyl)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-62-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(4-ethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-63-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(2,6-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-64-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-dichlorophenyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-65-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-66-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-67-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-dimethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-68-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethoxy)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-69-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-benzo[b]thien-2-yl-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762278-70-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,3-dichlorophenyl)-2-

thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-71-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(5-benzo[b]thien-3-yl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-72-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(5-chloro-2-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762278-73-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-cyanophenyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-74-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-(4-methylphenyl)-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-75-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-[2,4-bis(trifluoromethyl)phenyl]-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-76-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-chloro-4-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-77-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(1-methylethoxy)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762278-78-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-aminophenyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-79-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[2,3'-bithiophen]-5-ylcarbonyl)methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-80-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-(2-nitrophenyl)-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-81-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-benzofuranyl)-2-thienyl]carbonyl)methylamino]-N-[(3R)-1-cyclobutyl-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-82-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-83-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(2-methoxy-5-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-84-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(4-methoxy-2-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-85-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-(3,3,5,5-tetramethylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-86-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3,3,5,5-tetramethylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-87-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[3-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-88-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-89-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-90-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-91-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-92-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(4-bromobenzoyl)methylamino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-93-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-N-methyl-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762278-94-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-N-methyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 762278-95-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762278-96-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-

pyrrolidinyl]-N-methyl-3-[methyl [[[(1R,2S) -2-phenylcyclopropyl] amino] carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-97-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[(3,4-difluorophenyl)amino]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762278-98-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl [[[(3-methylphenyl) methyl] amino] carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

Me

RN 762278-99-9 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(2-naphthalenylamino)carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Cl


RN 762279-00-5 HCAPLUS
CN 1-Pyrrolidinecarboxamide, 3-[[[[(1,1'-biphenyl)-4-ylamino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762279-01-6 HCAPLUS
CN 1-Pyrrolidinecarboxamide, 3-[[[[(4-bromophenyl)amino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-02-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[4-phenoxyphenyl]amino]carbonyl]amino]-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-03-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[[1R,2S]-2-phenylcyclopropyl]amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-04-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[[1R,2S]-2-phenylcyclopropyl]amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-05-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-06-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-3-[methyl[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-07-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[4-(4-fluorophenoxy)phenyl]amino]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762279-08-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[1-(2-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Ph

RN 762279-09-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[1-(2-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


PAGE 1-B




RN 762279-12-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[4-(3-hydroxyphenoxy)phenyl]amino]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762279-13-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[2,3-dihydro-1,4-benzodioxin-2-yl]amino]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Cl


RN 762279-14-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[[4-(4-nitrophenoxy)phenyl]amino]carbonylamino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762279-15-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-[3,5-bis(trifluoromethyl)phenoxy]phenyl]amino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762279-16-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[(1,2-diphenylethyl)amino]carbonyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-17-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[5-[4-chlorophenyl]thio]-3-thienyl]amino]carbonyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Cl


RN 762279-18-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[(5-chlorobenzo[b]thien-2-yl)methyl]amino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762279-19-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(2-methyl-1,5-diphenyl-1H-pyrrol-3-yl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-20-9 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[(1,2-benzisoxazol-3-ylmethyl)amino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762279-21-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(5-(2-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)amino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-22-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[[(2-quinoxalinythio)methyl]amino]carbon-yl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762279-23-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[2-(4-chlorophenoxy)-3-pyridinyl]amino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Cl


RN 762279-24-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenoxy)phenyl]amino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762279-25-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[[4-(phenylsulfonyl)phenyl]amino]carbonyl]

]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-26-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[3,5-dimethyl-4-(phenylmethoxy)phenyl]amino]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


— Ph

RN 762279-27-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chloro-3-fluorophenoxy)phenyl]amino]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762279-28-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(6-phenoxy-3-pyridinyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-29-8 HCAPLUS

CN 1-Piperidinecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-4-(4-fluorophenyl)-N-

methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-30-1 HCAPLUS

CN 1-Piperidinecarboxamide, 4-(4-fluorophenyl)-N-methyl-N-[(3S)-1-[[methyl[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-31-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[4-phenoxyphenyl]amino]carbonyl]amino]-N-[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-32-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(cyclobutylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[[4-phenoxyphenyl]amino]carbonyl]amino]-, (3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 762279-33-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(1-methylethyl)-3-pyrrolidinyl]-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-34-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(cyclohexylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-35-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-chlorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-36-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-37-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclohexylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-38-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-39-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-40-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-chlorocyclopentyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-41-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(2-methylcyclopentyl)-3-pyrrolidinyl]-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762279-43-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclohexyl-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-44-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-chlorocyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762279-45-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(3-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-46-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-47-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-acetyl-4-piperidinyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-48-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-49-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[(3R)-1-[4-(trifluoromethyl)phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-50-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[(3R)-1-(2-methylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-51-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-52-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(cyclopropylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-53-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-cyclohexyl-1-methylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-54-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-hydroxybutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762279-55-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-cyclobutylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-56-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-cyclopentyl-1-methylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-57-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-ethylcyclopentyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-58-3 HCAPLUS

CN Cyclopentanecarboxylic acid, 2-[(3R)-3-[methyl[(3S)-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-59-4 HCAPLUS

CN Pentitol, 1,4-anhydro-2,3,5-trideoxy-3-[(3R)-3-[methyl[(3S)-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-60-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-ethylcyclopentyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762279-61-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1,1'-bicyclopentyl]-2-yl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-62-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(1,1-dimethylpropyl)cyclopentyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-63-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[(3R)-1-[(tetrahydro-3-furanyl)methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-64-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4-phenoxyphenyl) amino]carbonyl] amino]-N-[(3R)-1-(1H-pyrrol-2-ylmethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-65-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[(3R)-3-methylcyclopentyl]-3-pyrrolidinyl]-3-[methyl[[4-phenoxyphenyl) amino]carbonyl] amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-66-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[4-phenoxyphenyl)amino]carbonyl]amino]-N-[(3R)-1-(2-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-67-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[4-phenoxyphenyl)amino]carbonyl]amino]-N-[(3R)-1-(2,4,4-trimethylcyclopentyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-68-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-cyclohexylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 762279-69-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-70-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(4-phenoxyphenyl)amino]carbonyl]amino-, (3S)- (9CI) (CA INDEX NAME)

pyrrolidinyl]-3-[methyl[[[4-phenoxyphenyl][4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-71-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-3-[methyl[[[4-phenoxyphenyl](phenylmethyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-72-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[[(2-fluorophenyl)methyl](4-phenoxyphenyl)amino]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-73-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3-fluorophenyl)methyl] (4-phenoxyphenyl) amino] carbonyl] methylamino]-N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-74-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3-cyanophenyl)methyl] (4-phenoxyphenyl) amino] carbonyl] methylamino]-N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-75-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2,5-difluorophenyl)methyl](4-phenoxyphenyl)amino]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-76-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(3,5-difluorophenyl)methyl](4-phenoxyphenyl)amino]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-77-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(2,4-difluorophenyl)methyl] (4-phenoxyphenyl)amino]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762279-78-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4-chlorophenyl)methyl] (4-phenoxyphenyl)amino]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-methylcyclopentyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762279-79-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(1H-indol-3-yl)-1-methylethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762279-80-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-[(4-chlorophenyl)thio]-1-methylethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762279-81-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-methyl-2-(phenylsulfonyl)ethyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762279-82-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-bicyclo[3.3.1]non-9-yl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-83-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762279-84-5 HCAPLUS

CN 3-Oxazolidinecarboxylic acid, 2,2-dimethyl-4-[[[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-85-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4-cyclohexylbutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762279-86-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-hydroxybutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762279-87-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[3-(3,4,5-trimethoxyphenyl)propyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762279-88-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(3,4-dimethoxyphenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762279-89-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(2-methoxyphenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃


RN 762279-90-3 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762279-91-4 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762279-92-5 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[3-[3-[(2-methyl-1-oxopropyl)amino]phenyl]propyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762279-93-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-fluorophenyl)-3-oxopropyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762279-94-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762279-95-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-[(4-chlorophenyl)sulfonyl]ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762279-96-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-methoxyphenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762279-97-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(2-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762279-98-1 HCAPLUS

CN Carbamic acid, methyl[(1S)-1-[[[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762279-99-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[3-(2-methylphenyl)propyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-00-2 HCAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]methyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762280-01-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(3,4-difluorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762280-02-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(3-fluorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762280-03-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4,6-dimethoxy-2-pyrimidinyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762280-04-6 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762280-05-7 HCAPLUS

CN 1-Pyrrolidinepropanamide, β -methyl-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762280-06-8 HCAPLUS

CN 1-Pyrrolidinepropanoic acid, β -(2-methoxyethyl)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-07-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(2,2,6,6-tetramethyl-4-piperidinyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-08-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[1-(tetrahydro-5-oxo-2-furanyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-09-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-methoxy-1,3-dimethylbutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃


RN 762280-10-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





IT 762280-11-5P 762280-12-6P 762280-13-7P
 762280-14-8P 762280-15-9P 762280-16-0P
 762280-17-1P 762280-18-2P 762280-19-3P
 762280-20-6P 762280-21-7P 762280-22-8P
 762280-23-9P 762280-24-0P 762280-25-1P
 762280-26-2P 762280-27-3P 762280-28-4P
 762280-29-5P 762280-30-8P 762280-31-9P
 762280-32-0P 762280-33-1P 762280-35-3P
 762280-36-4P 762280-37-5P 762280-38-6P
 762280-39-7P 762280-40-0P 762280-41-1P
 762280-42-2P 762280-43-3P 762280-44-4P
 762280-45-5P 762280-46-6P 762280-47-7P
 762280-48-8P 762280-49-9P 762280-50-2P
 762280-51-3P 762280-52-4P 762280-53-5P
 762280-54-6P 762280-55-7P 762280-56-8P
 762280-57-9P 762280-58-0P 762280-59-1P
 762280-60-4P 762280-61-5P 762280-62-6P
 762280-63-7P 762280-64-8P 762280-65-9P
 762280-66-0P 762280-67-1P 762280-68-2P
 762280-69-3P 762280-70-6P 762280-71-7P
 762280-72-8P 762280-73-9P 762280-74-0P
 762280-75-1P 762280-76-2P 762280-77-3P
 762280-78-4P 762280-79-5P 762280-80-8P
 762280-81-9P 762280-82-0P 762280-83-1P
 762280-84-2P 762280-85-3P 762280-86-4P
 762280-87-5P 762280-88-6P 762280-89-7P
 762280-90-0P 762280-91-1P 762280-92-2P
 762280-94-4P 762280-95-5P 762280-96-6P
 762280-97-7P 762280-98-8P 762280-99-9P
 762281-00-5P 762281-01-6P 762281-02-7P
 762281-03-8P 762281-04-9P 762281-05-0P
 762281-06-1P 762281-07-2P 762281-08-3P
 762281-09-4P 762281-10-7P 762281-11-8P
 762281-12-9P 762281-13-0P 762281-15-2P
 762281-16-3P 762281-17-4P 762281-18-5P
 762281-19-6P 762281-20-9P 762281-21-0P
 762281-22-1P 762281-23-2P 762281-24-3P
 762281-25-4P 762281-26-5P 762281-27-6P
 762281-28-7P 762281-29-8P 762281-30-1P
 762281-31-2P 762281-33-4P 762281-34-5P
 762281-35-6P 762281-36-7P 762281-37-8P
 762281-39-0P 762281-40-3P 762281-41-4P
 762281-42-5P 762281-43-6P 762281-44-7P
 762281-45-8P 762281-46-9P 762281-47-0P
 762281-48-1P 762281-49-2P 762281-50-5P

762281-51-6P 762281-52-7P 762281-53-8P
 762281-54-9P 762281-55-0P 762281-56-1P
 762281-57-2P 762281-58-3P 762281-59-4P
 762281-60-7P 762281-61-8P 762281-62-9P
 762281-63-0P 762281-64-1P 762281-65-2P
 762281-66-3P 762281-67-4P 762281-68-5P
 762281-69-6P 762281-70-9P 762281-71-0P
 762281-72-1P 762281-73-2P 762281-74-3P
 762281-75-4P 762281-76-5P 762281-77-6P
 762281-78-7P 762281-79-8P 762281-80-1P
 762281-81-2P 762281-82-3P 762281-83-4P
 762281-84-5P 762281-85-6P 762281-86-7P
 762281-87-8P 762281-88-9P 762281-89-0P
 762281-90-3P 762281-91-4P 762281-92-5P
 762281-93-6P 762281-94-7P 762281-95-8P
 762281-96-9P 762281-97-0P 762281-98-1P
 762281-99-2P 762282-00-8P 762282-01-9P
 762282-02-0P 762282-03-1P 762282-04-2P
 762282-05-3P 762282-06-4P 762282-07-5P
 762282-08-6P 762282-09-7P 762282-10-0P
 762282-11-1P 762282-12-2P 762282-13-3P
 762282-14-4P 762282-15-5P 762282-16-6P
 762282-17-7P 762282-18-8P 762282-20-2P
 762282-21-3P 762282-22-4P 762282-23-5P
 762282-24-6P 762282-25-7P 762282-26-8P
 762282-27-9P 762282-28-0P 762282-29-1P
 762282-30-4P 762282-31-5P 762282-32-6P
 762282-33-7P 762282-34-8P 762282-35-9P
 762282-36-0P 762282-37-1P 762282-38-2P
 762282-39-3P 762282-40-6P 762282-41-7P
 762282-42-8P 762282-43-9P 762282-44-0P
 762282-45-1P 762282-46-2P 762282-47-3P
 762282-48-4P 762282-49-5P 762282-50-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of carboxamidopyrrolidine derivs. as melanin-concentrating hormone receptor antagonists)

RN 762280-11-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1,4-dioxaspiro[4.5]dec-8-yl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762280-12-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1,1'-bicyclo[2.2.2]oct-2-yl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-13-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[1-(phenylmethyl)propyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-14-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-methoxycyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-15-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-cyclohexyl-1-methylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-16-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(1-methyl-4-piperidinyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-17-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(1-methyl-4-oxobutyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-18-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1'-(phenylmethyl)[1,3'-bipyrrolidin]-3-yl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762280-19-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-chlorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762280-20-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclopropylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762280-21-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-22-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-cyclobutylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-23-9 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[3-(3-pyridinyl)-2-propenyl]-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A






RN 762280-24-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-ethyl-4-piperidinyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-25-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(1 α ,3 α ,5 α)-3,5-dimethylcyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762280-26-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-27-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-cyclohexylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-28-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-ethoxy-1-methylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CF₃


RN 762280-29-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-methyl-3-

(methylthio)propyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-30-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-ethylcyclopentyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-31-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3,3-dimethylbutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-32-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3,3,3-trifluoropropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-33-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-ethyl-2-hydroxybutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-35-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(1α,3α,4α)-3,4-dimethylcyclopentyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-36-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(5-hydroxypentyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-37-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-hydroxy-1-methylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-38-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-cyclopentyl-1-methylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-39-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3,3,3-trifluoro-1-methylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-40-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-fluoro-1-methylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-41-1 HCAPLUS

CN Cyclohexanecarboxylic acid, 2-[(3R)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-42-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(2-thiazolylmethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-43-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[(tetrahydro-3-furanyl)methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-44-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[(1-methyl-1H-imidazol-2-yl)methyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-45-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2,2-dimethoxyethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-46-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[3-(methylthio)butyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-47-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(ethylthio)-1-methylethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-48-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1,2-dimethylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-49-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[3-methyl-1-(2-methylpropyl)butyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-50-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-ethyl-2-methylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-51-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-ethylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-52-4 HCAPLUS

CN Pentitol, 1,4-anhydro-2,3,5-trideoxy-3-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-53-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(1,3,3-trimethylbutyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-54-6 HCAPLUS

CN 1-Pyrrolidinepropanoic acid, β-methyl-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-55-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(1-methyl-3-phenylpropyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-56-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-methoxy-1-methylethyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-57-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(cyclopropylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-58-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


—CF₃

RN 762280-59-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1,3-benzodioxol-5-ylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762280-60-4 HCAPLUS

CN Cycloheptanecarboxylic acid, 2-[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-61-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4-cyano-1-methylbutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃


RN 762280-62-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-furanylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762280-63-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3-phenylbutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-64-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(1-methylbutyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-65-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(1-methylbutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-66-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(1-methylbutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-67-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[(1-methyl-1H-pyrrol-2-yl)methyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-68-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-furanylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-69-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(5-ethyl-2-furanyl)methyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-70-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-71-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2,2-dimethoxy-1-methylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-72-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(4-chlorophenyl)methyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-73-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(3-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-74-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(cyclohexylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-75-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclobutyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-76-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-77-3 HCAPLUS

CN Cyclopentanecarboxylic acid, 2-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-78-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(2-methylcyclopentyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-79-5 HCAPLUS

CN Cyclohexaneacetic acid, 2-[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762280-80-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(4-methoxyphenyl)methyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762280-81-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(2,4-dimethoxyphenyl)methyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-82-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cycloheptyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-83-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1H-imidazol-2-ylmethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-84-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-ethyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-85-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-propyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-86-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[3-(methylthio)propyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-87-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-butyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762280-88-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[4-(1-

methylethyl)phenyl)methyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762280-89-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[4-(trifluoromethyl)phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762280-90-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(2-methylpropyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-91-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(4-pyridinylmethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-92-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-hydroxy-1-methylpropyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-94-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-hydroxy-1-methylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-95-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-96-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[(3-methyl-2-thienyl)methyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-97-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-cyclopropylethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-98-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(2-pyridinylmethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762280-99-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-acetyl-4-piperidinyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-00-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762281-01-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-methoxycyclopentyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-02-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3-oxo-1-cyclopenten-1-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-03-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3-phenyl-2-propenyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 762281-04-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4-hydroxy-1-methylbutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


—CF₃

RN 762281-05-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(2,4-dimethoxyphenyl)-1-methylethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-06-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-07-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(cis-4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-08-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(trans-4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-09-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-10-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(cis-4-ethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-11-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(trans-4-ethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-12-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(cis-4-propylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762281-13-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(trans-4-propylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CF₃


RN 762281-15-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(phenylthio)ethyl]-3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 762281-14-1
CMF C33 H37 F3 N4 O2 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 762281-16-3 HCAPLUS
CN 1-Pyrrolidinepropanamide, N-(1-methylethyl)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762281-17-4 HCAPLUS
CN 1-Pyrrolidinepropanamide, 3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-


pyrrolidinyl]carbonyl]amino]-N-(phenylmethyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-18-5 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[3-(4-morpholinyl)-3-oxopropyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-19-6 HCAPLUS

CN 1-Pyrrolidinepropanamide, N-(1,1-dimethylethyl)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762281-20-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[3-oxo-3-(1-pyrrolidinyl)propyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-21-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-oxopropyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762281-22-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-[(2R,6S)-2,6-dimethyl-1-piperidinyl]-3-oxopropyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-23-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3-oxobutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-24-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-fluorophenyl)-1-oxopropyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-25-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(3R)-3-amino-1-oxo-3-phenylpropyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762281-26-5 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(2S)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-27-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-28-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(phenylsulfinyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-29-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(ethylsulfonyl)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-30-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[2-[(4-methylphenyl)sulfonyl]ethyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-31-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-[(phenylmethyl)sulfonyl]ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 762281-33-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(1-pyrrolidinylsulfonyl)ethyl]-

Prvor, 10. 79.792.7


3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 762281-32-3

CMF C31 H40 F3 N5 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 762281-34-5 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-[(cyclohexylethylamino)sulfonyl]ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-35-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-[[cyclohexyl(1-methylethyl)amino]sulfonyl]ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-36-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]sulfonyl]ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-37-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-39-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[2-[(2-methyl-1-pyrrolidinyl)sulfonyl]ethyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-40-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(1-piperidinylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-41-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(aminoiminomethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-42-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(cyclopentyloxy)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-43-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-ethoxyethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762281-44-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-[(tetrahydro-3-furanyl)oxy]ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-45-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(1H-benzotriazol-1-yl)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-46-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[2-(1-methylethoxy)ethyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-47-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(2-oxo-3(2H)-benzoxazolyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-48-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762281-49-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(1H-benzimidazol-1-yl)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-50-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[4-methyl-2-[[methyl(phenylmethyl)amino]methyl]phenyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

(trifluoromethyl) [1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CF₃

RN 762281-51-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[4-methyl-2-[(methylamino)methyl]phenyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-52-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-[(dimethylamino)methyl]-4-methylphenyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 762281-53-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-54-9 HCAPLUS


CN 1-Piperidinecarboxamide, N-(1,1-dimethylethyl)-4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-55-0 HCAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-56-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[1-(1-oxopropyl)-4-piperidinyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


$$-\text{CF}_3$$

RN 762281-57-2 HCAPLUS


1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-(3,3-dimethyl-1-oxobutyl)-4-piperidinyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-58-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-(methoxyacetyl)-4-piperidinyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-59-4 HCAPLUS


CN 1-Piperidinecarboxamide, N,N-dimethyl-4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-60-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl) [1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CF₃

RN 762281-61-8 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CF₃

RN 762281-62-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-[(ethylamino)thioxomethyl]-4-piperidinyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CF₃


RN 762281-63-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-64-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-[(1-methylethyl)amino][(1-methylethyl)imino]methyl]-4-piperidinyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-65-2 HCAPLUS


CN 1-Piperidinecarboxamide, N-(3,5-dimethyl-4-isoxazolyl)-4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-66-3 HCAPLUS

CN 1-Piperidinecarbothioic acid, 4-[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, O-phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762281-67-4 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, 2-methylpropyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-68-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3R)-3-[methyl[(3S)-3-[methyl[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CF₃

RN 762281-69-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-(methylsulfonyl)-4-piperidinyl]-3-pyrrolidinyl]-3-[methyl[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762281-70-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[1-[(trifluoromethyl)sulfonyl]-4-piperidinyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-71-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[1-(1-pyrrolidinylcarbonyl)-4-piperidinyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-72-1 HCAPLUS


CN 1-Piperidinecarboxamide, N,N-diethyl-4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762281-73-2 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, 1-methylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-74-3 HCAPLUS


CN 1-Piperidinecarboxamide, N,N-dimethyl-3-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-75-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



1-Piperidinecarboxylic acid, 3-[(3R)-3-[methyl[(3S)-3-[methyl[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CF₃

RN 762281-77-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-(methoxyacetyl)-3-piperidinyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762281-78-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-acetyl-3-piperidinyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-79-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-[(1-methylethyl)sulfonyl]-3-piperidinyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-80-1 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[(3R)-3-[methyl[[3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-81-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[1-(1-oxopropyl)-3-piperidinyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-82-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-(3,3-dimethyl-1-oxobutyl)-3-piperidinyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-83-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-(methanesulfonyl)-3-piperidinyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CF₃

RN 762281-84-5 HCAPLUS


CN 1-Piperidinecarboxamide, N-(1,1-dimethylethyl)-3-[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-85-6 HCAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-3-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-86-7 HCAPLUS


CN 1-Piperidinecarboxamide, N-(1-methylethyl)-3-[(3R)-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-87-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-[(dimethylamino)thioxomethyl]-3-piperidinyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762281-88-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[1-[(trifluoromethyl)sulfonyl]-3-piperidinyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CF₃

RN 762281-89-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-[(ethylamino)thioxomethyl]-3-piperidinyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




CF₃

RN 762281-90-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(trans-4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-91-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(trans-4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-92-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(cis-4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-

thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-93-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(cis-4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-94-7 HCAPLUS


CN 5-Isoxazolecarboxamide, 3-(4-chlorophenyl)-N-methyl-N-[(3S)-1-[[methyl[(3R)-1-(cis-4-methylcyclohexyl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-95-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-N-[(3R)-1-(cis-4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-96-9 HCAPLUS
 CN 5-Isoxazolecarboxamide, 3-(4-chlorophenyl)-N-methyl-N-[(3S)-1-[[methyl[(3R)-1-(trans-4-methylcyclohexyl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762281-97-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-N-[(3R)-1-(trans-4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 762281-98-1 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762281-99-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

—Bu-t

RN 762282-00-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[(5-phenyl-2-thienyl)carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-01-9 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-02-0 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-03-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]carbonyl]methylamino]-N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-04-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(4-methoxybenzoyl)methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-05-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[5-(4-chlorophenyl)-1,5-dioxopentyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-06-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-07-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[5-(4-chlorophenyl)-1,5-dioxopentyl]methylamino]-N-methyl-N-[(3R)-1-[3-(methylthio)butyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-08-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-[(3R)-1-[(3-methoxyphenyl)methyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-09-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-[(3R)-1-[(2-fluoro-5-methylphenyl)methyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-10-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-

methyl-N-[(3R)-1-[[2-(methylthio)phenyl]methyl]-3-pyrrolidinyl]-, (3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-11-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-
[(3R)-1-[(3-fluoro-4-methoxyphenyl)methyl]-3-pyrrolidinyl]-N-methyl-,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 762282-12-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[5-(4-chlorophenyl)-1,5-
dioxopentyl]methylamino]-N-[(3R)-1-[(3-fluoro-4-methoxyphenyl)methyl]-3-
pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 762282-13-3 HCAPLUS

CN 5-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N,4-dimethyl-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-14-4 HCAPLUS

CN 4-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-15-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-16-6 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, 5-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 762282-17-7 HCAPLUS

CN 4-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-2-(2,3-dihydro-5-benzofuranyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 762282-18-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[4-(4-chlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762282-20-2 HCAPLUS
 CN 5-Isioxazolecarboxamide, 3-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-21-3 HCAPLUS
 CN 4-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-

pyrrolidinyl)methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-22-4 HCAPLUS

CN 5-Isioxazolecaboxamide, N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl)methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-23-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(3S)-1-[[[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl)methylamino]carbonyl]-3-pyrrolidinyl]-N,2,5-trimethyl-1-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-24-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-3-[[[4-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-25-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-methoxyphenyl)acetyl]methylamino]-N-methyl-N-[(3R)-1-[3-(4-methylphenoxy)phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762282-26-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-27-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-28-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-29-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclobutyl-3-pyrrolidinyl]-3-[[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-30-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclobutyl-3-pyrrolidinyl]-3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-31-5 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-cyclobutyl-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-32-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-[(3R)-1-cyclobutyl-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-33-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclobutyl-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-34-8 HCAPLUS

CN 5-Isoxazolecarboxamide, 3-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-cyclobutyl-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762282-35-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]-3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



RN 762282-36-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]-3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-37-1 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-38-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-[(3,5-dichlorophenyl)methyl]-2-furanyl]carbonyl]methylamino]-N-[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Cl

RN 762282-39-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-40-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— OMe

RN 762282-41-7 HCAPLUS

CN 5-Isioxazolecarboxamide, 3-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-42-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(ethylsulfonyl)ethyl]-3-pyrrolidinyl]-3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



F


RN 762282-43-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-[(3R)-1-[2-(ethylsulfonyl)ethyl]-3-pyrrolidinyl]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-44-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(ethylsulfonyl)ethyl]-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762282-45-1 HCAPLUS
 CN 5-Isoxazolecarboxamide, 3-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-[2-(ethylsulfonyl)ethyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-46-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-47-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-ethoxyphenyl]acetyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-48-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[(2-naphthalenyloxy)acetyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-49-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]-3-[[[4-ethoxyphenyl]acetyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-50-8 HCAPLUS

CN 5-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 762282-51-9P 762282-52-0P 762282-53-1P
 762282-54-2P 762282-55-3P 762282-56-4P
 762282-57-5P 762282-58-6P 762282-59-7P
 762282-60-0P 762282-61-1P 762282-62-2P
 762282-63-3P 762282-64-4P 762282-65-5P
 762282-66-6P 762282-67-7P 762282-68-8P
 762282-69-9P 762282-72-4P 762282-73-5P
 762282-74-6P 762282-75-7P 762282-76-8P
 762282-77-9P 762282-78-0P 762282-79-1P
 762282-80-4P 762282-81-5P 762282-82-6P

762282-83-7P 762282-84-8P 762282-85-9P
 762282-86-0P 762282-87-1P 762282-88-2P
 762282-89-3P 762282-90-6P 762282-91-7P
 762282-92-8P 762282-93-9P 762282-94-0P
 762282-95-1P 762282-96-2P 762282-97-3P
 762282-98-4P 762282-99-5P 762283-00-1P
 762283-01-2P 762283-02-3P 762283-03-4P
 762283-18-1P 762283-19-2P 762283-20-5P
 762283-21-6P 762283-22-7P 762283-23-8P
 762283-24-9P 762283-25-0P 762283-26-1P
 762283-27-2P 762283-28-3P 762283-29-4P
 762283-30-7P 762283-31-8P 762283-32-9P
 762283-33-0P 762283-34-1P 762283-35-2P
 762283-36-3P 762283-37-4P 762283-38-5P
 762283-39-6P 762283-40-9P 762283-41-0P
 762283-42-1P 762283-43-2P 762283-44-3P
 762283-45-4P 762283-46-5P 762283-47-6P
 762283-48-7P 762283-49-8P 762283-50-1P
 762283-51-2P 762283-52-3P 762283-53-4P
 762283-54-5P 762283-55-6P 762283-56-7P
 762283-57-8P 762283-58-9P 762283-59-0P
 762283-61-4P 762283-62-5P 762283-63-6P
 762283-64-7P 762283-65-8P 762283-66-9P
 762283-67-0P 762283-68-1P 762283-69-2P
 762283-70-5P 762283-71-6P 762283-73-8P
 762283-74-9P 762283-75-0P 762283-76-1P
 762283-77-2P 762283-78-3P 762283-79-4P
 762283-80-7P 762283-81-8P 762283-82-9P
 762283-83-0P 762283-85-2P 762283-86-3P
 762283-87-4P 762283-88-5P 762283-89-6P
 762283-90-9P 762283-91-0P 762283-92-1P
 762283-93-2P 762283-94-3P 762283-95-4P
 762283-96-5P 762283-98-7P 762283-99-8P
 762284-00-4P 762284-01-5P 762284-02-6P
 762284-03-7P 762284-05-9P 762284-06-0P
 762284-07-1P 762284-08-2P 762284-09-3P
 762284-10-6P 762284-11-7P 762284-12-8P
 762284-13-9P 762284-14-0P 762284-15-1P
 762284-16-2P 762284-17-3P 762284-18-4P
 762284-19-5P 762284-20-8P 762284-21-9P
 762284-22-0P 762284-23-1P 762284-24-2P
 762284-25-3P 762284-26-4P 762284-27-5P
 762284-28-6P 762284-29-7P 762284-30-0P
 762284-31-1P 762284-32-2P 762284-33-3P
 762284-34-4P 762284-35-5P 762284-36-6P
 762284-37-7P 762284-38-8P 762284-39-9P
 762284-40-2P 762284-41-3P 762284-42-4P
 762284-43-5P 762284-44-6P 762284-45-7P
 762284-46-8P 762284-47-9P 762284-48-0P
 762284-49-1P 762284-50-4P 762284-51-5P
 762284-52-6P 762284-53-7P 762284-54-8P
 762284-55-9P 762284-56-0P 762284-57-1P
 762284-58-2P 762284-59-3P 762284-60-6P
 762284-61-7P 762284-62-8P 762284-63-9P
 762284-64-0P 762284-65-1P 762284-66-2P
 762284-67-3P 762284-68-4P 762284-69-5P
 762284-70-8P 762284-71-9P 762284-72-0P
 762284-73-1P 762284-74-2P 762284-75-3P
 762284-76-4P 762284-77-5P 762284-78-6P
 762284-79-7P 762284-80-0P 762284-82-2P

762284-83-3P 762284-84-4P 762284-85-5P
 762284-86-6P 762284-87-7P 762284-88-8P
 762284-89-9P 762284-90-2P 762284-91-3P
 762284-92-4P 762284-93-5P 762284-94-6P
 762284-95-7P 762284-96-8P 762284-98-0P
 762284-99-1P 762285-00-7P 762285-01-8P
 762285-02-9P 762285-03-0P 762285-04-1P
 762285-05-2P 762285-06-3P 762285-07-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of carboxamidopyrrolidine derivs. as
 melanin-concentrating hormone receptor antagonists)

RN 762282-51-9 HCAPLUS

CN 5-Thiazolecarboxamide, N-methyl-N-[(3S)-1-[[methyl[(3R)-1-(tetrahydro-2H-
 pyran-4-yl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]-2-[4-
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-52-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[[2-chloro-4-
 (dimethylamino)phenyl]methyl]-3-pyrrolidinyl]-3-[[5-(4-chlorophenyl)-1,5-
 dioxopentyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


NMe₂

RN 762282-53-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[(4-methoxybenzoyl)methylamino]-N-methyl-N-
[(3R)-1-[[3-(4-methylphenoxy)phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762282-54-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[([1,1'-biphenyl]-4-ylcarbonyl)methylamino]-N-methyl-N-[(3R)-1-[[3-(4-methylphenoxy)phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762282-55-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl(2-naphthalenylcarbonyl)amino]-
 N-[(3R)-1-[[3-(4-methylphenoxy)phenyl]methyl]-3-pyrrolidinyl]-, (3S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762282-56-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[(4-ethoxybenzoyl)methylamino]-N-methyl-N-
 [(3R)-1-[[3-(4-methylphenoxy)phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 762282-57-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[1-(4-methylphenyl)cyclopropyl]carbonyl]amino]-N-[(3R)-1-[[3-(4-methylphenoxy)phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-58-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-[(3R)-1-[[2-chloro-4-(dimethylamino)phenyl]methyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-59-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[5-(4-chlorophenyl)-1,5-dioxopentyl]methylamino]-N-methyl-N-[(3R)-1-[[3-(4-methylphenoxy)phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762282-60-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl)methylamino]-N-methyl-N-[(3R)-1-[[5-[2-(trifluoromethyl)phenyl]-2-furanyl)methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-61-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[[2-chloro-4-(dimethylamino)phenyl)methyl]-3-pyrrolidinyl]-N-methyl-3-[methyl(2-naphthalenylcarbonyl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-62-2 HCAPLUS

Prvpr 19_79/927

CN 1-Pyrrolidinecarboxamide, 3-[[5-(4-chlorophenyl)-1,5-dioxopentyl]methylamino]-N-methyl-N-[(3R)-1-[[5-[2-(trifluoromethyl)phenyl]-2-furanyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762282-63-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-methyl-N-[(3R)-1-[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-64-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-methyl-N-[(3R)-1-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762282-65-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[5-(4-chlorophenyl)-1,5-dioxopentyl]methylamino]-N-methyl-N-[(3R)-1-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762282-66-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-N-[(3R)-1-[[4,5-dimethyl-2-furanyl]methyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-67-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl)methylamino]-N-[(3R)-1-[(6-chloro-4-oxo-4H-1-benzopyran-3-yl)methyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-68-8 HCAPLUS

CN 4-Oxazoleacetamide, N-[(3S)-1-[[[(3R)-1-[[2-chloro-4-(dimethylamino)phenyl]methyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N,5-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-69-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl)methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-72-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-difluorocyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-73-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4-fluoro-3-cyclohexen-1-yl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-74-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(trans-4-hydroxy-4-methylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-75-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(cis-4-hydroxy-4-methylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-76-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[4-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]benzoyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-77-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(2-chloro-5-pyrimidinyl)benzoyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-78-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl 4-[5-(trifluoromethyl)-2-pyridinyl]benzoyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-79-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[4-(6-methoxy-3-pyridazinyl)benzoyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-80-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-(1-propynyl)-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-81-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-(phenylethynyl)-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-82-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-(1,2-propadienyl)-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-83-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[4'-ethyl[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-84-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-bromophenyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-85-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(1,3-benzodioxol-5-yl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-86-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(1,3-benzodioxol-5-yl)benzoyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-87-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)benzoyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762282-88-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(6-bromo-3-pyridinyl)-2-

thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-89-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl 4-[6-(trifluoromethyl)-3-pyridinyl]benzoyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-90-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)benzoyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-91-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-[(diethylamino)methyl]-4,4-dimethylcyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-92-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4,4-dimethyl-1-[(2-oxo-1-pyrrolidinyl)methyl]cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-93-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4,4-dimethyl-1-[[[(methylsulfonyl)amino]methyl]cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-94-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4,4-dimethyl-1-(1H-1,2,3-triazol-1-ylmethyl)cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-95-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-(1,4,4-trimethylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-96-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-(tetrahydro-4-methyl-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-97-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-acetyl-4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-98-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3S)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762282-99-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3S)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-00-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-01-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-02-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-03-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-18-1 HCAPLUS

CN 5-Isoxazolecarboxamide, 3-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-cyclopentyl-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-19-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-20-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-chloro[1,1'-biphenyl]-4-

yl)carbonyl]methylamino]-N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-,
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-21-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-22-7 HCAPLUS

CN 5-Isoxazolecarboxamide, 3-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-23-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— F

RN 762283-24-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-25-0 HCAPLUS

CN 1H-Imidazole-4-carboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-26-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(3-fluoro-4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-27-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

thienyl]carbonylamino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-28-3 HCAPLUS

CN 5-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-2-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-29-4 HCAPLUS

CN 5-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-2-[(4-fluorophenyl)amino]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-30-7 HCAPLUS

CN 5-Thiazolecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-2-[(4-methylphenyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-31-8 HCAPLUS


CN 5-Isioxazolecarboxamide, 3-(4-chlorophenyl)-N-methyl-N-[(3S)-1-[[methyl[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-32-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-33-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4'-(4-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-34-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-35-2 HCAPLUS
 CN 5-Isoxazolecarboxamide, 3-(4-chlorophenyl)-N-methyl-N-[(3S)-1-
 [[methyl[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-
 pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762283-36-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-
 methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-,
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

F


RN 762283-37-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-38-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762283-39-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-fluoro-4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-40-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-41-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]-3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-42-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-43-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


OMe

RN 762283-44-3 HCAPLUS

CN 5-Isoxazolecarboxamide, 3-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Cl


RN 762283-45-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-
 [(3R)-1-(3-hydroxybutyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 762283-46-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-
 yl)carbonyl]methylamino]-N-[(3R)-1-(3-hydroxybutyl)-3-pyrrolidinyl]-N-
 methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-47-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-hydroxybutyl)-3-pyrrolidinyl]-3-
 [[[(5-(4-methoxyphenyl)-2-thienyl)carbonyl]methylamino]-N-methyl-, (3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-48-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-acetyl-4-piperidinyl)-3-pyrrolidinyl]-3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

F

RN 762283-49-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-acetyl-4-piperidinyl)-3-pyrrolidinyl]-3-[[[4'-chloro[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-50-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-acetyl-4-piperidinyl)-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-51-2 HCAPLUS

CN 5-Isoxazolecarboxamide, N-[(3S)-1-[[[(3R)-1-(1-acetyl-4-piperidinyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-3-(4-chlorophenyl)-N-methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762283-52-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-N-[(3R)-1-[1-(methylsulfonyl)-4-piperidinyl]-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762283-53-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4'-(4-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-[1-(methylsulfonyl)-4-piperidinyl]-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Cl


RN 762283-54-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-[1-(methylsulfonyl)-4-piperidinyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-55-6 HCAPLUS
 CN 5-Isioxazolecarboxamide, 3-(4-chlorophenyl)-N-methyl-N-[(3S)-1-
 [[methyl[(3R)-1-[1-(methylsulfonyl)-4-piperidinyl]-3-
 pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-56-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclopentyl-3-oxopropyl)-3-
 pyrrolidinyl]-3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-, (3S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762283-57-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-
 yl)carbonyl]methylamino]-N-[(3R)-1-(3-cyclopentyl-3-oxopropyl)-3-
 pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-58-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-[(3R)-1-(2-methoxyethyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-59-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-[(3R)-1-(2-methoxyethyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-61-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-methoxyethyl)-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-62-5 HCAPLUS

CN 5-Isioxazolecarboxamide, 3-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-63-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 762283-64-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762283-65-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-66-9 HCAPLUS

CN 5-Isioxazolecarboxamide, 3-(4-chlorophenyl)-N-methyl-N-[(3S)-1-[[methyl[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-67-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-N-[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-68-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-69-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-70-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-3-[methyl(1-oxo-4-phenoxybutyl)amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-71-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-73-8 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-cyclopentyl-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N,5-dimethyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-74-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]carbonyl]methylamino]-N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-75-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-3-[[[5-(3,5-dichlorophenoxy)-2-furanyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-76-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl(1-oxo-4-phenoxybutyl)amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-77-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-78-3 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N,5-dimethyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-79-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-80-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3,5-dichlorophenoxy)-2-furanyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-81-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl(1-oxo-4-phenoxybutyl)amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-82-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-83-0 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N,5-dimethyl-N-[(3S)-1-[[methyl[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-85-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-86-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3,5-dichlorophenoxy)-2-furanyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-87-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-3-[methyl(1-oxo-4-phenoxybutyl)amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-88-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-89-6 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N,5-dimethyl-N-[(3S)-1-[[methyl[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-90-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-91-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3,5-dichlorophenoxy)-2-methyl-3-furanyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-92-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]-3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762283-93-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-N-[(3R)-1-[1-(methylsulfonyl)-4-piperidinyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-94-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-N-[(3R)-1-[1-(methylsulfonyl)-4-piperidinyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


mino]-N-[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762283-95-4 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(3S)-1-[[[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762283-96-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3,5-dichlorophenoxy)-2-furanyl]carbonyl]methylamino]-N-[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-Cl


RN 762283-98-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-N-[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762283-99-8 HCAPLUS
 CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N,5-dimethyl-N-[(3S)-1-[[methyl[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-00-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3,5-dichlorophenoxy)-2-furanyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-01-5 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-3-[methyl[(2-phenylcyclopropyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-02-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[(2-phenylcyclopropyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762284-03-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[(2-phenylcyclopropyl)amino]carbonyl]amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-05-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-[2-methoxy-5-(1-methylethyl)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 762284-04-8
 CMF C27 H38 N4 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 762284-06-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(5-fluoro-2-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-07-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-benzo[b]thien-2-yl-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-08-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chloro-4-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-09-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chloro-2-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762284-10-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chloro-2-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-11-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3,4-dimethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

(3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-12-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(methoxysulfonyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762284-13-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-dichlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-14-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-[4-(acetylamino)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-15-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,3-dichlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-16-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[2-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-17-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-fluoro-6-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-18-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(1-methylethoxy)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-19-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,5-dichlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

(3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-20-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[2-(1-methylethoxy)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-21-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[3-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-22-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chloro-4-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidiny]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-23-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-chloro-4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidiny]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-24-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-chloro-2-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidiny]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-25-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxy-2,6-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-26-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-27-5 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-fluoro-3-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-28-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-fluoro-5-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-29-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-30-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-fluoro-3-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-31-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762284-32-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-fluoro-2-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-33-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxy-2-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

(3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-34-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(6-methoxy-3-pyridinyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-35-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethoxy)phenyl]-2-thienyl]carbonyl]amino]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-36-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-ethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-37-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-cyanophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-38-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(methylthio)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-39-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-fluoro-2-methylphenyl)-2-

thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-40-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-(2-methylphenyl)-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-41-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-(4-methylphenyl)-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-42-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-43-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762284-44-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-45-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3,4-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-46-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,6-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-47-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

(3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-48-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-49-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-50-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-chlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-51-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,3-difluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-52-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-difluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-53-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-benzofuranyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-54-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-acetylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-55-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,3-dihydro-5-benzofuranyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-56-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(1-methylethyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762284-57-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-[4-(dimethylamino)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-58-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(1,3-benzodioxol-5-yl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-59-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-60-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-61-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-62-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-methoxy-5-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-63-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-chloro-4-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-64-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3-chloro-4-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

(3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-65-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-ethoxy-3-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-66-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-[4-[(dimethylamino) carbonyl]phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-67-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(5-chloro-2-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-68-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-69-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[3'-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-70-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-methoxy-2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-71-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(6-methoxy-3-pyridinyl)benzoyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-72-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-73-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4'-ethyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-74-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4'-(4-ethylphenyl)phenyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-75-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(methylthio)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-76-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4'-(4-fluoro-2-methyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-77-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-3-[[[5-(4-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-78-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-79-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-80-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-82-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-hydroxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762284-83-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(methylsulfonyl)phenyl]-2-

thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-84-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(4-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-85-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[2-(methylthio)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-86-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[3-(methylthio)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-87-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(3-fluoro-2-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-88-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(6-fluoro-3-pyridinyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-89-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-3-[[[5-(6-methoxy-3-pyridinyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-90-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chloro-3-pyridinyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-91-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(6-chloro-3-pyridinyl)-2-thienyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-92-4 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-6-(3-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-93-5 HCAPLUS

CN 3-Pyridinecarboxamide, 6-(2,3-dihydro-5-benzofuranyl)-N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-94-6 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-95-7 HCAPLUS

CN 3-Pyridinecarboxamide, 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762284-96-8 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(3S)-1-[[[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]methylamino]carbonyl]-3-pyrrolidinyl]-6-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762284-98-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 762284-97-9

CMF C31 H38 F3 N5 O3


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 762284-99-1 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-cyclopentyl-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762285-00-7 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-(1-methylethyl)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-01-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-oxo-2-(1-piperidinyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762285-02-9 HCAPLUS
 CN 1-Pyrrolidineacetamide, 3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-N-(2-methylpropyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-03-0 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-methyl-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-N-(2-methylpropyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762285-04-1 HCAPLUS


CN 1-Pyrrolidineacetamide, N-(cyclopropylmethyl)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762285-05-2 HCAPLUS

CN 1-Pyrrolidineacetamide, N,N-diethyl-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-06-3 HCAPLUS

CN 1-Pyrrolidineacetamide, N-(1,1-dimethylethyl)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762285-07-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(4-morpholinyl)-2-oxoethyl]-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CF₃

IT 762285-08-5P 762285-09-6P 762285-10-9P

762285-11-0P 762285-13-2P 762285-14-3P
 762285-15-4P 762285-16-5P 762285-17-6P
 762285-18-7P 762285-19-8P 762285-20-1P
 762285-21-2P 762285-23-4P 762285-24-5P
 762285-25-6P 762285-26-7P 762285-27-8P
 762285-28-9P 762285-29-0P 762285-31-4P
 762285-32-5P 762285-33-6P 762285-35-8P
 762285-36-9P 762285-37-0P 762285-38-1P
 762285-39-2P 762285-40-5P 762300-82-3P
 763130-65-0P 763130-66-1P 763130-67-2P
 763130-68-3P 763130-69-4P 763130-70-7P
 763130-71-8P 763130-72-9P 763130-73-0P
 763130-74-1P 763130-75-2P 763130-76-3P
 763130-77-4P 763130-78-5P 763130-79-6P
 763130-80-9P 763130-81-0P 763130-83-2P
 763130-84-3P 763130-85-4P 763130-86-5P
 763130-87-6P 763130-88-7P 763130-89-8P
 763130-90-1P 763130-91-2P 763130-92-3P
 763130-93-4P 763130-94-5P 763130-95-6P
 763130-96-7P 763130-97-8P 763130-98-9P
 763130-99-0P 763131-00-6P 763131-01-7P
 763131-02-8P 763131-03-9P 763131-04-0P
 763131-05-1P 763131-06-2P 763131-08-4P
 763131-09-5P 763131-10-8P 763131-11-9P
 763131-12-0P 763131-13-1P 763131-14-2P
 763131-15-3P 763131-16-4P 763131-17-5P
 763131-18-6P 763131-19-7P 763131-20-0P
 763131-21-1P 763131-22-2P 763131-23-3P
 763131-25-5P 763131-26-6P 763131-27-7P
 763131-28-8P 763131-29-9P 763131-31-3P
 763131-32-4P 763131-33-5P 763131-34-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of carboxamidopyrrolidine derivs. as melanin-concentrating hormone receptor antagonists)

RN 762285-08-5 HCAPLUS

CN 1-Pyrrolidineacetamide, N-cyclohexyl-3-[methyl[(3S)-3-[methyl[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762285-09-6 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-ethyl-N-methyl-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 762285-10-9 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-cyclohexyl-N-methyl-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 762285-11-0 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-(cyclohexylmethyl)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-13-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(1-azetidiny)-2-oxoethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 762285-12-1
 CMF C30 H36 F3 N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 762285-14-3 HCAPLUS


CN 1-Pyrrolidineacetamide, N-(2-cyanoethyl)-N-methyl-3-[methyl[[(3S)-3-[methyl[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-15-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[2-(4-methyl-1-piperidiny)-2-oxoethyl]-3-pyrrolidinyl]-3-[methyl[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-16-5 HCAPLUS


CN 1-Pyrrolidineacetamide, N-cyclohexyl-N-ethyl-3-[methyl[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-17-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(3,3-dimethyl-1-piperidiny)-2-oxoethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-18-7 HCAPLUS

1-Pyrrolidineacetamide, N-methyl-N-(1-methylethyl)-3-[methyl[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-19-8 HCAPLUS


1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-20-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-acetyl-1-piperazinyl)-2-oxoethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-21-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-oxo-2-(4-thiomorpholinyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762285-23-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(2-oxopropyl)-3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 762285-22-3
 CMF C28 H33 F3 N4 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 762285-24-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(1-methyl-2-oxopropyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-25-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762285-26-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-fluorophenyl)-2-oxoethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 762285-27-8 HCAPLUS


1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-chlorophenyl)-2-oxoethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 762285-28-9 HCAPLUS

1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(2-oxo-2-phenylethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762285-29-0 HCAPLUS

CN	1-Pyrrolidineacetic acid, 3-[methyl[[(3S)-3-[methyl[[4'-
----	--

Prior, 10_797927.

(trifluoromethyl) [1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762285-31-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 762285-30-3

CMF C31 H39 F3 N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 762285-32-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(tetrahydro-2H-pyran-4-

yl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 762285-33-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[5-[4-(1-methylethyl)phenyl]-2-thienyl]carbonyl]amino]-N-[(3R)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762285-35-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[3-(4-chlorophenyl)propyl]-3-pyrrolidinyl]-N-methyl-3-[methyl([1,1':4',1''-terphenyl]-4-ylcarbonyl)amino]-, (3S)-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 762285-34-7


CMF C39 H43 Cl N4 O2

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM . 2

CRN 75-75-2


CMF C H4 O3 S



RN 762285-36-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chloro-4-methylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 762285-37-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chloro-2-methylphenyl)-2-

thienyl]carbonyl]methylamino]-N-methyl-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762285-38-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-dichlorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 762285-39-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2-chloro-4-ethoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 762285-40-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(2,4-dimethylphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 762300-82-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-chlorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763130-65-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl](phenylmethyl)amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763130-66-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl][(4-fluorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763130-67-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl][(4-cyanophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 763130-68-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl][(3,5-dichlorophenyl)methyl]amino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763130-69-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-methyl-N-[(3S)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 763130-70-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763130-71-8 HCAPLUS

CN 1-Piperidinecarboxamide, 4-(4-fluorophenyl)-N-methyl-N-[(3S)-1-[[methyl[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763130-72-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[4-phenoxyphenyl]amino]carbonyl]amino]-N-[(3R)-1-(4-phenylcyclohexyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763130-73-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[[4-phenoxyphenyl]amino]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763130-74-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[4-(1-methylethyl)cyclohexyl]-3-pyrrolidinyl]-3-[methyl[[[4-phenoxyphenyl]amino]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763130-75-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[4-phenoxyphenyl) amino] carbonyl] amino]-N-[(3R)-1-(4-propylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763130-76-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[4-phenoxyphenyl) amino] carbonyl] amino]-N-[(3R)-1-[4-(trifluoromethyl)cyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763130-77-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl] carbonyl] amino]-N-[(3R)-1-(4-phenylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763130-78-5 HCAPLUS


CN Carbamic acid, [4-[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 763130-79-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763130-80-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(4-propylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 763130-81-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[4-(1-methylethyl)cyclohexyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 763130-83-2 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 763130-84-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[4-(trifluoromethyl)cyclohexyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 763130-85-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4-(1,1-dimethylethyl)cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃

RN 763130-86-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-methoxy-4-methylcyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763130-87-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[4-[[[(trifluoromethyl) sulfonyl]amino]cyclohexyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 763130-88-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4-[(3,3-dimethyl-1-oxobutyl)amino]cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 763130-89-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4-[(methoxyacetyl)amino]cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 763130-90-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4-(acetylamino)cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃


RN 763130-91-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[4-[(1-pyrrolidinylcarbonyl)amino]cyclohexyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 763130-92-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[4-[(methylsulfonyl)amino]cyclohexyl]-3-pyrrolidinyl]-3-[methyl[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 763130-93-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4-[(cyclobutylcarbonyl)amino]cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 763130-94-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4-[[[(1,1-dimethylethyl)amino]carbonyl]amino]cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 763130-95-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[4-[[[(ethylamino)carbonyl]amino]cyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 763130-96-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[4-[[[(1-methylethyl)amino]carbonyl]amino]cyclohexyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 763130-97-8 HCAPLUS


CN Carbamic acid, [4-[(3R)-3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]cyclohexyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 763130-98-9 HCAPLUS
 CN Carbamic acid, [4-[(3R)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]cyclohexyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 763130-99-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[4-[(1-oxopropyl)amino]cyclohexyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 763131-00-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methy
 lamino]-N-[(3R)-1-cyclobutyl-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 763131-01-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methy
 lamino]-N-[(3R)-1-(2,3-dihydro-1H-inden-2-yl)-3-pyrrolidinyl]-N-methyl-,
 (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-02-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-[(3R)-1-[2-(ethylsulfonyl)ethyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-03-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-04-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4-hydroxycyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763131-05-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(1-oxaspiro[3.5]non-7-yl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 763131-06-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-08-4 HCAPLUS

CN 5-Isioxazolecarboxamide, 3-(4-chlorophenyl)-N-methyl-N-[(3S)-1-[[methyl[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-09-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-10-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[4-(4-fluorophenoxy)benzoyl]methylamino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-11-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylanino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-12-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylanino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-13-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylanino]-N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-14-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-15-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(tetrahydro-2H-pyran-4-yl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763131-16-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)

pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-17-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-[(3R)-1-(3-cyclopentylpropyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-18-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-[(3R)-1-(3-hydroxybutyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-19-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(1-acetyl-4-piperidinyl)-3-pyrrolidinyl]-3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-20-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-[(3R)-1-(3-cyclopentyl-3-oxopropyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-21-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-[(3R)-1-(2-methoxyethyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763131-22-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 763131-23-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(4-chlorophenyl)cyclohexyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 763131-25-5 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 763131-24-4

CMF C30 H41 Cl N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 763131-26-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]methylamino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-27-7 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N,5-dimethyl-N-[(3S)-1-[[methyl[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]amino]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-28-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl(1-oxo-4-phenoxybutyl)amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-29-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[5-(3,5-dichlorophenoxy)-2-furanyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 763131-31-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[(2-phenylcyclopropyl)amino]carbonyl]amino]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 763131-30-2

CMF C28 H43 N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 763131-32-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[1-methyl-2-(methylsulfonyl)ethyl]-3-pyrrolidinyl]-3-[methyl[(2-phenylcyclopropyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-33-5 HCAPLUS


CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-fluorophenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763131-34-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 762285-73-4P 762285-74-5P 762285-76-7P
 762285-77-8P 762285-80-3P 762285-81-4P
 762285-84-7P 762285-85-8P 762285-97-2P
 762285-98-3P 762285-99-4P 762286-00-0P
 762286-01-1P 762286-02-2P 762286-05-5P
 762286-06-6P 762286-12-4P 762286-13-5P
 762286-23-7P 762286-25-9P 762286-27-1P
 762286-30-6P 763131-35-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of carboxamidopyrrolidine derivs. as
 melanin-concentrating hormone receptor antagonists)
 RN 762285-73-4 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[2-[(3S)-3-[[[1,1'-biphenyl]-4-ylcarbonyl]methylamino]-1-pyrrolidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-74-5 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-(3-pyrrolidinylacetyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-76-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N,2-dimethyl-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-3-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-77-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N,2-dimethyl-N-(3R)-3-pyrrolidinyl-3-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-80-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(4-bromobenzoyl)methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-81-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(4-bromo-2-methylbenzoyl)methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-84-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl)methylamino]-N-methyl-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-85-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl)methylamino]-N-methyl-N-(3S)-3-pyrrolidinyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-97-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4-phenoxyphenyl)amino]carbonyl]amino]-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-98-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762285-99-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762286-00-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-hydroxyethyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762286-01-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-[2-[(methylsulfonyl)oxy]ethyl]-3-pyrrolidinyl]-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CF₃

RN 762286-02-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(2-formyl-4-methylphenyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonylamino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762286-05-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(4-bromobenzoyl)methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762286-06-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[(5-bromo-2-thienyl)carbonyl]methylamino]-N-[(3R)-1-(4,4-dimethylcyclohexyl)-3-pyrrolidinyl]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762286-12-4 HCAPLUS

CN Carbamic acid, [[4,4-dimethyl-1-[(3R)-3-[methyl[[[(3S)-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-1-pyrrolidinyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762286-13-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[1-(aminomethyl)-4,4-dimethylcyclohexyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762286-23-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(5-bromo-2-thienyl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762286-25-9 HCAPLUS

CN 1-Pyrrolidineacetic acid, 3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762286-27-1 HCAPLUS


CN 1-Pyrrolidineacetic acid, 3-[methyl[[[(3S)-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 762286-26-0

CMF C27 H31 F3 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 762286-30-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-[[[(5-bromo-2-thienyl)carbonyl]methylamino]-N-methyl-N-(3R)-3-pyrrolidinyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 763131-35-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-(4-aminocyclohexyl)-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

Handwritten notes:
 25-H
 Q4 = Hek-293 (sub 5)
 Q3 = H
 X = NH
 n = 2
 m = 1
 R1 = sub 51 Heter

CF₃

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:904207 HCAPLUS

DOCUMENT NUMBER: 136:37902

TITLE: Preparation of 2-aminocarbonyl-9H-purine nucleosides and their uses in treatment of respiratory disease, as A2a receptor agonists and anti-inflammatory agents

INVENTOR(S): Mantell, Simon John; Stephenson, Peter Thomas

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 198 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094368	A1	20011213	WO 2001-IB973	20010605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, <u>US</u> , UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 227240	B1	20050201	TW 2001-90113146	20010531
CA 2414018	AA	20011213	CA 2001-2414018	20010605
US 2002058641	A1	20020516	US 2001-874007	20010605
US 6753322	B2	20040622		
EP 1292604	A1	20030319	EP 2001-934242	20010605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011263	A	20030617	BR 2001-11263	20010605
CN 1434830	A	20030806	CN 2001-810802	20010605
JP 2003535871	T2	20031202	JP 2002-501916	20010605
NZ 522184	A	20040528	NZ 2001-522184	20010605
EE 200200678	A	20040615	EE 2002-678	20010605
CN 1810822	A	20060802	CN 2006-10004588	20010605
BG 107216	A	20030530	BG 2002-107216	20021023

NO 2002005821	A	20030204	NO 2002-5821	20021204
ZA 2002009875	A	20031205	ZA 2002-9875	20021205
US 2004077584	A1	20040422	US 2003-676782	20031001
US 7094769	B2	20060822		
US 2006122145	A1	20060608	US 2006-334144	20060117
PRIORITY APPLN. INFO.:			GB 2000-14048	A 20000606
			GB 2000-18246	A 20000725
			GB 2000-24920	A 20001011
			US 2000-214307P	P 20000627
			US 2000-225236P	P 20000815
			US 2000-245243P	P 20001102
			CN 2001-810802	A3 20010605
			US 2001-874007	A3 20010605 ✓
			WO 2001-IB973	W 20010605
			US 2003-676782	A3 20031001

OTHER SOURCE(S): MARPAT 136:37902
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 2-Aminocarbonyl-9H-purine nucleosides I wherein R, R2 are independently H, alkyl; R1 is H, substituted alkyl, fluorenyl; R3 is H, alkyl, cycloalkyl, benzyl; R4 is substituted azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl; R3R4 taken together with the nitrogen atom to which they are attached, represent azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by alkyl or cycloalkyl; R5 is CH2OH, amide; X is substituted alkylene; RX or R2X with the nitrogen atom to which they are attached, represent azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl; Y is CO, CS, SO2, C=N(CN); were prepared as A2a receptor agonists and anti-inflammatory agents. Thus, nucleoside II was prepared and tested as A2a receptor agonist and anti-inflammatory agent. Title compds. were tested for biol. activity as A2a receptor agonists and anti-inflammatory agents and all were found to have an IC50 of less than 100 nM.

IT 380221-82-9P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aminocarbonyl-9H-purine nucleosides and uses in treatment of respiratory disease, as A2a receptor agonists and anti-inflammatory agents)

RN 380221-82-9 HCAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[(3R)-1-[[[1-(2-pyridinyl)-4-piperidinyl]amino]carbonyl]-3-pyrrolidinyl]amino]carbonyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => fil reg

FILE 'REGISTRY' ENTERED AT 17:13:32 ON 08 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2006 HIGHEST RN 906063-52-3
DICTIONARY FILE UPDATES: 7 SEP 2006 HIGHEST RN 906063-52-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> => d his

(FILE 'HOME' ENTERED AT 17:00:34 ON 08 SEP 2006)

FILE 'REGISTRY' ENTERED AT 17:01:26 ON 08 SEP 2006

L1 STR
L2 34 S L1
L3 857 S L1 FUL

FILE 'HCAPLUS' ENTERED AT 17:07:43 ON 08 SEP 2006

L4 4 S L3
SELECT HIT RN 1-4

FILE 'REGISTRY' ENTERED AT 17:10:42 ON 08 SEP 2006


L6 835 S E1-E835
L7 22 S L3 NOT L6

FILE 'REGISTRY' ENTERED AT 17:13:32 ON 08 SEP 2006

=> d ide can l7 1-22

L7 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
RN 794479-70-2 REGISTRY
ED Entered STN: 08 Dec 2004
CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H39 F3 N4 O2
CI COM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 2 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
RN 763131-30-2 REGISTRY
ED Entered STN: 15 Oct 2004
CN 1-Pyrrolidinecarboxamide, N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-3-[methyl[(2-phenylcyclopropyl)amino]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H43 N5 O2
CI COM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 3 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 763131-24-4 REGISTRY
 ED Entered STN: 15 Oct 2004
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-(4-methylcyclohexyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H41 Cl N4 O3
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 4 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762286-26-0 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidineacetic acid, 3-[methyl[[[(3S)-3-[methyl[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H31 F3 N4 O4
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 5 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762285-30-3 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H39 F3 N4 O3
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 6 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762285-22-3 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-(2-oxopropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H33 F3 N4 O3
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 7 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762285-12-1 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(1-azetidiny)-2-oxoethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H36 F3 N5 O3
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 8 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762284-97-9 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H38 F3 N5 O3
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 9 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762284-04-8 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidinecarboxamide, 3-[[[5-[2-methoxy-5-(1-methylethyl)phenyl]-2-thienyl]carbonyl]methylamino]-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H38 N4 O3 S
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 10 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762281-14-1 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidinecarboxamide, N-methyl-3-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-N-[(3R)-1-[2-(phenylthio)ethyl]-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H37 F3 N4 O2 S
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 11 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-27-3 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidinecarboxamide, 3-[[[(3'-fluoro-2',4'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-N-methyl-N-[(3R)-1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C35 H43 F N4 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 12 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-23-9 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[(1-cyclobutyl-3-pyrrolidinyl)acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H35 N3 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 13 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-21-7 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-[(1-methyl-3-pyrrolidinyl)acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H31 N3 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 14 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-19-3 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[[1-(1-cyclohexylethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H43 N3 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 15 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-17-1 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[[1-(cyclohexylmethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H41 N3 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 16 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-15-9 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[[1-(2,2-diphenylethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C38 H41 N3 O2
 CI COM
 SR CA

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 17 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-13-7 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[[1-(cyclopropylmethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C28 H35 N3 O2
CI COM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 18 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
RN 762278-11-5 REGISTRY
ED Entered STN: 14 Oct 2004
CN [1,1'-Biphenyl]-4-carboxamide, N-[(3S)-1-[(1-cyclohexyl-3-pyrrolidinyl)acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H39 N3 O2
CI COM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 19 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
RN 762278-09-1 REGISTRY
ED Entered STN: 14 Oct 2004
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-[(1-pentyl-3-pyrrolidinyl)acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H39 N3 O2
CI COM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 20 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-07-9 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-[[1-(3-phenylpropyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H39 N3 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 21 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762278-05-7 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[(3S)-1-[(1-(phenylmethyl)-3-pyrrolidinyl]acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H35 N3 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 ANSWER 22 OF 22 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 762277-96-3 REGISTRY
 ED Entered STN: 14 Oct 2004
 CN 1-Pyrrolidinecarboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl)amino]-N-methyl-
 N-[1-(3-phenylpropyl)-3-pyrrolidinyl]-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H38 N4 O2
 CI COM
 SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> => d stat que l14
 L1 STR




VAR G1=AK/CY/18
 VAR G2=CH2/N
 REP G3=(1-2) CH2
 REP G4=(0-1) CH2
 NODE ATTRIBUTES:
 NSPEC IS RC AT 18
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
 L3 857 SEA FILE=REGISTRY SSS FUL L1
 L4 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L3

L10

STR



N@18

VAR G1=AK/CY/18

VAR G2=CH2/N

NODE ATTRIBUTES:

NSPEC IS RC AT 18

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L11 915 SEA FILE=REGISTRY SSS FUL L10

L12 58 SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT L3

L13 22 SEA FILE=HCAPLUS ABB=ON PLU=ON L12

L14 22 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 NOT L4

=>

=>

=> d ibib abs hitstr l14 1-22

L14 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:215845 HCAPLUS

DOCUMENT NUMBER: 142:298011

TITLE: Preparation of isoquinolinones and their use as selective c-Jun N-terminal kinase (JNK) inhibitors and (pro)drugs

INVENTOR(S): Fukumoto, Masashi; Asano, Yasuomi; Ikata, Hideki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 219 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005060247	A2	20050310	JP 2003-207418	20030812
PRIORITY APPLN. INFO.:			JP 2003-207418	20030812
OTHER SOURCE(S):	MARPAT	142:298011		

GI



I

AB Title compds. I [ring A, B maybe substituted; X = divalent aliphatic hydrocarbylene; R1 = H, (un)substituted OH, (un)substituted SH, (un)substituted SO2, (un)substituted amino, acyl, cyano, (un)substituted nonarom. hydrocarbon ring, etc.; R2 = similar group as in R1 except H], useful for treatment of JNK-related diseases, e.g., heart failure, arteriosclerosis, rheumatoid arthritis, asthma, and Alzheimer's disease, are prepared. Thus, treatment of 6-chloro-4-phenyl-3-propionyl-1,2-dihydroisoquinolin-1-one with NaH and 2-(3-bromopropyl)isoindoline-1,3-dione gave 5% 2-[3-(6-chloro-1-oxo-4-phenyl-3-propionyl-1,2-dihydroisoquinolin-2-yl)propyl]isoindoline-1,3-dione, which at 10 μ M inhibited >90% human JNK1.


IT 847767-67-3P 847767-91-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinolinones as selective c-Jun N-terminal kinase inhibitors and (pro)drugs)


RN 847767-67-3 HCAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[2-[3-(acetylamino)-1-pyrrolidinyl]-2-oxoethyl]-6-bromo-1,2-dihydro-1-oxo-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 847767-91-3 HCAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[2-[3-(acetylamino)-1-pyrrolidinyl]-2-oxoethyl]-1,2-dihydro-1-oxo-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)




L14 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:802720 HCAPLUS
 DOCUMENT NUMBER: 141:314159
 TITLE: Preparation of lactam-containing cyclic diamines and derivatives as factor Xa inhibitors for treating thromboembolic disorders
 INVENTOR(S): Qiao, Jennifer X.; Wang, Tammy C.; Wang, Gren Z.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 260 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082687	A1	20040930	WO 2004-US8088	20040317
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004204454	A1	20041014	US 2004-801469	20040316
EP 1603572	A1	20051214	EP 2004-757541	20040317
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRIORITY APPLN. INFO.:			US 2003-455733P	P 20030318
			US 2003-508232P	P 20031002
			US 2004-801469	A 20040316
			WO 2004-US8088	W 20040317
OTHER SOURCE(S):	MARPAT 141:314159			
GI				



- AB Title compds. of formula G-G1-M-Z-A-B [wherein M = central ring selected from (un)substituted optionally fused cyclopentane, or cyclohexane, (un)substituted tetrahydropyran, piperidine, piperidin-2-one, pyrrolidine, etc.; G = benzofused ring; G1 = (CH₂)₁₋₅ and derivs., (un)substituted CH₂:CH₂, C(:O), NH, NHCO SO₂NH, SO₂NHCO, all of the above optionally substituted on one or both ends with alkylene groups, etc., with provisos; Z = NHCO, CONH, Z = (CH₂)₁₋₅ and derivs., (un)substituted NHCO, CONH, CO, NHC(:S)NH, S, SO, SO₂, SONH, SO₂NH, all of the above optionally substituted on one or both ends with alkylene groups, etc.; A = (un)substituted carbo- or heterocycle; B = lactam or sulfam bound to A ring through an optional linking group attached to the N, pharmaceutically acceptable salts] were prepared as inhibitors of trypsin-like serine proteases, specifically factor Xa, for treating thromboembolic disorders. For example, I was prepared by reductive amination of 4-(2-oxo-2H-pyridin-1-yl)benzaldehyde (preparation given) with (1R,2S)-5-Chlorothiophene-2-carboxylic acid (2-aminocyclopentyl)amide in CH₂Cl₂ in the presence of NaBH(OAc)₃/AcOH. Selected invention compds. displayed K_i ≤ 10 μM in a spectrophotometrical assay using purified human factor Xa.
- IT 766556-22-3P, 5-Chloro-N-[(3R,4S)-4-[[4-(2-oxo-2H-pyridin-1-yl)benzoyl]amino]-1-[2-(tetrahydro-2H-pyran-4-yl)acetyl]pyrrolidin-3-yl]thiophene-2-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (factor Xa inhibitor; preparation of lactam-containing cyclic diamines and derivs. as factor Xa inhibitors for treating thromboembolic disorders)
- RN 766556-22-3 HCAPLUS
- CN 2-Thiophenecarboxamide, 5-chloro-N-[(3R,4S)-4-[[4-(2-oxo-1(2H)-pyridinyl)benzoyl]amino]-1-[(tetrahydro-2H-pyran-4-yl)acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:780362 HCAPLUS
 DOCUMENT NUMBER: 141:295864
 TITLE: Preparation of sulfonamide lactams as Factor Xa inhibitors
 INVENTOR(S): O'Connor, Stephen P.; Lawrence, Michael; Shi, Yan; Stein, Philip D.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 257 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004186134	A1	20040923	US 2003-374299	20030226
PRIORITY APPLN. INFO.:			US 2003-374299	20030226
OTHER SOURCE(S):	MARPAT 141:295864			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Sulfonamide lactams of formula 1 [wherein X = (un)substituted (CH₂)_m; m = 1-3; R₁ = (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl, cycloheteroalkyl; R₂, R₃ = independently H, (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl, cycloheteroalkyl; R₄, R_{4a}, R₅, R_{5a} = independently H, OH, alkoxy, CO₂H and derivs., CONH₂ and derivs., S(O)qH and derivs., SO₂NH₂ and derivs., etc. (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl, cycloheteroalkyl; q = 0-2; R₆, R_{6a} = independently H, (un)substituted alk(en/yn)yl, cycloalkyl, substituted hetero/aryl, cycloheteroalkyl; R₇, R₈ = independently (un)substituted (CH₂)_n-H or R₇NR₈ = (un)substituted cycloheteroalkyl; n = 1-4; with the proviso that certain compds. are absent; their pharmaceutically acceptable salts, stereoisomers and prodrugs] were prepared as inhibitors of Factor Xa and useful as anticoagulants in the treatment of cardiovascular diseases

associated with thromboses (no data). For instance, reacting amine II with naphthalene-2-sulfonyl chloride in CH₂Cl₂ in the presence of TEA for 30 min at room temperature gave sulfonamide III in 66% yield.

IT 445270-73-5P 445272-53-7P 445274-09-9P
445274-17-9P 445274-26-0P 445274-45-3P
445274-52-2P 445274-59-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of sulfonamide lactams as factor Xa inhibitors and anticoagulants).

RN 445270-73-5 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445272-53-7 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 445274-09-9 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 445274-17-9 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(5-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-26-0 HCAPLUS

CN Acetamide, N-methyl-N-[1-[[[(3S)-3-[[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-45-3 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(4-amino-3-chlorophenyl)sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-52-2 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[4-(acetylamino)-3-chlorophenyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-59-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[4-[[[(3S)-1-[2-[3-(acetylmethylamino)-1-pyrrolidinyl]-2-oxoethyl]-2-oxo-3-piperidinyl]amino]sulfonyl]-2-chlorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:964345 HCAPLUS

DOCUMENT NUMBER: 138:24952

TITLE: Preparation of novel amino nitriles useful as reversible inhibitors of cysteine proteases

INVENTOR(S): Hickey, Eugene R.; Bekkali, Younes; Patel, Usha R.; Spero, Denice M.; Thomson, David S.; Young, Erick R.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2002100849	A2	20021219	WO 2002-US17590	20020605
WO 2002100849	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003119827	A1	20030626	US 2002-163015	20020604
US 6982263	B2	20060103		
CA 2449192	AA	20021219	CA 2002-2449192	20020605
EP 1399431	A2	20040324	EP 2002-741825	20020605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005501017	T2	20050113	JP 2003-503617	20020605
PRIORITY APPLN. INFO.:			US 2001-296863P	P 20010608
			WO 2002-US17590	W 20020605

OTHER SOURCE(S): MARPAT 138:24952

AB Novel nitrile compds. YCO2CR2R3C(:X)NR6CR4R5CN [Y = R1, R10, R1S, R12N, R13C, where R1 = H, (un)substituted (cyclo)alkyl, aryl, benzyl, tetrahydronaphthyl, indenyl, indanyl, alkylsulfonylalkyl, cycloalkylsulfonylalkyl, arylsulfonylalkyl, heterocyclyl, or heteroaryl; R2-R5 = H, (un)substituted (cyclo)alkyl, aryl, etc. or CR2R3 and CR4R5 may form rings; R6 = H, OH, or (cyclo)alkyl; X = O or S (with provisos)] or their pharmaceutically-acceptable derivs. were prepared as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B for treating diseases and pathol. conditions exacerbated by these proteases such as osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, and atherosclerosis. Thus, morpholine-4-carboxylic acid 1-[[[(benzyloxymethyl)cyanomethyl]carbamoyl]-3-methylbutyl ester was prepared from N-(tert-butoxycarbonyl)-O-benzyl-L-serine, 2-Hydroxyisocaproic acid, and 4-morpholinecarbonyl chloride.


IT 478280-81-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel amino nitriles as reversible inhibitors of cysteine proteases)


RN 478280-81-8 HCAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-[[[3-cyano-1-(4-pyridinylacetyl)-3-pyrrolidinyl]amino]carbonyl]-3-methylbutyl ester (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 2002:927249 HCAPLUS
 DOCUMENT NUMBER: 138:14059
 TITLE: Preparation of spiro-fused hydantoin derivatives as inhibitors of matrix metalloproteinases
 INVENTOR(S): Sheppeck, James E.; Duan, Jingwu; Xue, Chu-Biao; Wasserman, Zelda
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 350 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096426	A1	20021205	WO 2002-US16381	20020523
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2447475	AA	20021205	CA 2002-2447475	20020523
US 2003130273	A1	20030710	US 2002-155575	20020523
US 6890915	B2	20050510		
EP 1397137	A1	20040317	EP 2002-741724	20020523
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004535411	T2	20041125	JP 2002-592936	20020523
US 2004209874	A1	20041021	US 2004-844219	20040512
US 6906053	B2	20050614		
US 2005171096	A1	20050804	US 2005-93670	20050330
PRIORITY APPLN. INFO.:			US 2001-293571P	P 20010525
			US 2002-155575	A3 20020523
			WO 2002-US16381	W 20020523
			US 2004-844219	A3 20040512
OTHER SOURCE(S):	MARPAT 138:14059			
GI				




I




II

- AB Title compds. I [R11 = W-U-X-Y-Z-Ua-Xa-Ya-Za; W = alkyl, alkenylene, alkynylene; U = absent, amino, CO, alkyl, carboxy, etc.; X = absent, alk(en/yn)ylene; Y = absent, O, amino, SOO-2, CO; Z = (hetero)cycle; Ua = absent, O, amino, CO, alkyl, carboxy, etc.; Xa = absent, alk(en/yn)ylene; Ya = absent, O, amino, SOO-2, CO; Za = (hetero)cycle; R1-2 together with the carbon atoms to which they are attached, combine to form a 3-8 membered carbocyclic or heterocyclic ring; R3 = H, CHF2, CH2F, CF3, alk(en/yn)ylene, etc.; R4-7 = H, alk(en/yn)yl; n = 0-1] were prepared For instance, 2-(ethylcarboxy)cyclohexanone was treated with ammonium carbonate and potassium cyanide (EtOHaq, 50°, 24 h) to afford the corresponding hydantoin ester which was hydrolyzed to the carboxylic acid and coupled to 4-[(2-methyl-4-quinolinyl)methoxy]aniline•2HCl (DMSO, PyBOP) to give II which was isolated as the trifluoroacetate. I are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.
- IT 477582-36-8P, 4-[(2-Methyl-4-quinolinyl)methoxy]-N-[7-(4-morpholinylacetyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]benzamide 477582-59-5P 477582-74-4P, 4-[(1,1-Dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl)methyl]-N-[7-(4-morpholinylacetyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]benzamide
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (hydantoin derivs. as inhibitors of matrix metalloproteinases)
- RN 477582-36-8 HCAPLUS
- CN Benzamide, 4-[(2-methyl-4-quinolinyl)methoxy]-N-[7-(4-morpholinylacetyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 477582-59-5 HCAPLUS
 CN Benzamide, 4-[(2-methyl-4-quinolinyl)methyl]-N-[7-(4-morpholinylacetyl)-
 2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]- (9CI) (CA INDEX NAME)




RN 477582-74-4 HCAPLUS
 CN Benzamide, 4-[(2,3-dihydro-1,1-dioxido-4H-1,4-benzothiazin-4-yl)methyl]-N-[7-(4-morpholinylacetyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:594840 HCAPLUS
 DOCUMENT NUMBER: 137:154858
 TITLE: Preparation of arylsulfonamidopiperidones as inhibitors of Factor Xa.
 INVENTOR(S): Stein, Philip P.; O'Connor, Stephen P.; Lawrence, R. Michael; Shi, Yan
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 246 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060894	A2	20020808	WO 2002-US2542	20020128
WO 2002060894	A3	20021219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2436774	AA	20020808	CA 2002-2436774	20020128
EP 1358178	A2	20031105	EP 2002-717381	20020128
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004518688	T2	20040624	JP 2002-561043	20020128
US 6555542	B1	20030429	US 2002-59621	20020129
PRIORITY APPLN. INFO.:			US 2001-264964P	P 20010130
			WO 2002-US2542	W 20020128
OTHER SOURCE(S):	MARPAT 137:154858			
GI				



I

AB Title compds. [I; X = (substituted) (CH₂)_m; m = 1-3; R₁ = (substituted) alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc.; R₂, R₃ = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R₄, R₄₁, R₅, R₅₁ = H, OH, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, alkoxy, etc.; R₆, R₆₁ = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R₇, R₈ = (substituted) (CH₂)_nH; n = 1-4; R₇R₈N = (substituted) cycloheteroalkyl], were prepared as cardiovascular agents (no data). 974 I, including (II), were prepared

IT 445270-73-5P 445272-53-7P 445274-09-9P
445274-17-9P 445274-26-0P 445274-45-3P
445274-52-2P 445274-59-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonamidopiperidones as inhibitors of Factor Xa)

RN 445270-73-5 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445272-53-7 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 445274-09-9 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(1E)-2-(5-chloro-2-

thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 445274-17-9 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[5-chlorobenzo[b]thien-2-yl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-26-0 HCAPLUS

CN Acetamide, N-methyl-N-[1-[[[(3S)-3-[[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-45-3 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[4-amino-3-chlorophenyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-52-2 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[4-(acetylamino)-3-chlorophenyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-59-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[4-[[[(3S)-1-[2-[3-(acetylmethylamino)-1-pyrrolidinyl]-2-oxoethyl]-2-oxo-3-piperidinyl]amino]sulfonyl]-2-chlorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L14 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:504757 HCAPLUS
 DOCUMENT NUMBER: 137:78855
 TITLE: Preparation of carbazoles as neuropeptide Y5 receptor ligands
 INVENTOR(S): Block, Michael Howard; Foote, Kevin Michael; Donald, Craig Samuel; Schofield, Paul
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051806	A1	20020704	WO 2001-GB5577	20011217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432008	AA	20020704	CA 2001-2432008	20011217
BR 2001016388	A	20030930	BR 2001-16388	20011217
EP 1358157	A1	20031105	EP 2001-272068	20011217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520324	T2	20040708	JP 2002-552903	20011217
CN 1531527	A	20040922	CN 2001-822825	20011217
NZ 526623	A	20041126	NZ 2001-526623	20011217
ZA 2003004764	A	20040920	ZA 2003-4764	20030619
NO 2003002842	A	20030818	NO 2003-2842	20030620
US 2004067999	A1	20040408	US 2003-450928	20031010
PRIORITY APPLN. INFO.:			GB 2000-31382	A 20001222
			GB 2001-21919	A 20010911
			WO 2001-GB5577	W 20011217

OTHER SOURCE(S):
GI

MARPAT 137:78855



AB The title compds. [I; R1 = alkyl, alkanoyl, alkylsulfonyl, etc.; R2, R3 = Me; or R2 and R3 together = (un)substituted (CH₂)₄ or (CH)₄; R4 = alkyl; R5 = CONR₉R₁₀, COR₉, COCOR₉; R6 = halo, CN, OH, etc.; R₉, R₁₀ = H, alkyl, alkoxy, etc.; or NR₉R₁₀ = (un)substituted heterocyclic ring; m = 0-2], useful as NPY 5 inhibitors in treating eating disorders, were prepared and formulated. Thus, amidation of 4-morpholinecarbonyl chloride with 3-amino-2,4-dimethyl-9-isopropyl-9H-carbazole in the presence of Et₃N in DCM afforded I [R1 = iso-Pr; R2 and R3 together = (CH)₄; R4 = Me; R5 = morpholinocarbonyl; R6 = 2-Me; m = 1]. In general, compds. I possess an IC₅₀ in the range 0.0002 to 200 μM against NPY₅.


IT 439862-23-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carbazoles as neuropeptide Y₅ receptor ligands)

RN 439862-23-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, 3-(acetylamino)-N-[4-methyl-9-(1-methylethyl)-9H-carbazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:830896 HCAPLUS

DOCUMENT NUMBER: 135:357846

TITLE: Preparation of ethylenediamine compound libraries as drugs

INVENTOR(S): Swayze, Eric Edward; Jefferson, Elizabeth Anne Campbell

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: U.S., 26 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6316623	B1	20011113	US 1998-138186	19980821
PRIORITY APPLN. INFO.:			US 1998-138186	19980821


OTHER SOURCE(S): MARPAT 135:357846

AB R5Z(CH2)pNR4CHR2CHR1NR3R6 [I; R1,R2 = H, alkyl, (hetero)aryl(alkyl), etc.; R3-R5 = H, amino-protective group, alkyl, alkanoyl, etc.; R6 = H or linked support; Z = azacycloalkylene; p = 0-3] were prepared Thus, RNTsCH2CH2NHSO2C6H4(NO2)-2 (R = linked resin, Ts = tosyl) was condensed with N-protected piperidine-4-methanol (preparation each given) and the product converted in 5 steps to PhCH2COZCH2N(COC6H4Me-3)CH2CH2NHTs (Z = piperidine-1,4-diyl). Data for biol. activity of I were given.

IT 372947-23-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ethylenediamine compound libraries as drugs)

RN 372947-23-4 HCAPLUS

CN Pyrazinecarboxamide, N-[2-[(cyclopropylcarbonyl)[1-[(tetrahydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-3-pyrrolidinyl]amino]ethyl]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:675178 HCAPLUS

DOCUMENT NUMBER: 136:184046

TITLE: Synthesis and evaluation of prolyl carbamate nucleic acids (PrCNA)

AUTHOR(S): Meena; Kumar, V. A.; Ganesh, K. N.

CORPORATE SOURCE: Division of Organic Chemistry (Synthesis), National Chemical Laboratory, Pune, 411008, India

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2001),
20(4-7), 1193-1196
CODEN: MNNAFY; ISSN: 1525-7770

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:184046

AB Carbamate linked prolyl nucleic acids are obtained in high yield and
purity under mild conditions in solution and solid phase.
P-Nitrophenylchloroformate is used as the activating reagent for alc.
Homooligomers of PrCNA do not bind to DNA. The introduction of this
modification in PNA sequences destabilizes the triplexes, inspite of
enhancement in the base stacking.


IT 380649-00-3P 380649-01-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(solid phase synthesis and evaluation of prolyl carbamate nucleic acids
(PrCNA))

RN 380649-00-3 HCAPLUS


CN Peptide nucleic acid, (H-T-T-T-T-T-T[imino[(2S,4S)-1-[(3,4-dihydro-5-
methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4,2-
pyrrolidinediyl]methyleneoxycarbonyl]T)-Bal-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-C


Me

RN 380649-01-4 HCAPLUS
 CN Peptide nucleic acid, (H-T-T-T[imino[(2S,4S)-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4,2-pyrrolidinediyl]methyleneoxycarbonyl]T-


T-T-T)-Bal-OH (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





Me

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:719708 HCAPLUS
 DOCUMENT NUMBER: 134:71562
 TITLE: Synthesis and NK1/NK2 receptor activity of substituted 4(Z)-(methoxyimino)pentyl-1-piperazines
 AUTHOR(S): Ting, P. C.; Lee, J. F.; Anthes, J. C.; Shih, N.-Y.; Piwinski, J. J.
 CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033-1300, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(20), 2333-2335
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:71562
 AB A series of 5-{[3,5-bis(trifluoromethyl)phenyl]methoxy}-3-(3,4-dichlorophenyl)-4(Z)-(methoxyimino)pentyl-1-piperazines was prepared and their affinity for the NK1 and NK2 receptors investigated. The compds. proved to be potent inhibitors.
 IT 315718-34-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and NK1/NK2 receptor inhibitory activity of
[(methoxyimino)pentyl]piperazines)


RN 315718-34-4 HCAPLUS

CN Acetamide, N-[1-[[4-[5-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl]-1-piperazinyl]acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:645989 HCAPLUS
 DOCUMENT NUMBER: 133:223047
 TITLE: Synthesis of proline derivatives
 INVENTOR(S): Hocker, Michael Douglas; Plunkett, Matthew
 PATENT ASSIGNEE(S): Axys Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053579	A2	20000914	WO 2000-US6021	20000308
WO 2000053579	A3	20001221		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-123631P P 19990310
 OTHER SOURCE(S): MARPAT 133:223047
 GI




AB Compds. R₄R₅NC(O)-Q-NR₁-Y-R₂ [R₁ is an alkyl radical which may be substituted by tertiary amine, aryl, or heteroaryl; R₂ = alkyl, (un)substituted aryl; R₄, R₅ = cycloalkyl, (un)substituted alkyl or R₄R₅N is an (un)substituted five to seven membered heterocyclic ring; Q represents a pyrrolidine-2,4-diyl radical which is N-substituted by 2-(un)substituted 2-hydroxyethyl or an acyl group and may be substituted at other ring positions; Y = S, SO, SO₂] were prepared by a process which enables individual, parallel, and simultaneous synthesis of a plurality of compds. Thus, proline derivative I was prepared by a protocol involving epoxide ring opening, carboxylic acid acylation, linker activation and amine cleavage.

IT 292177-85-6P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
(Preparation)
(synthesis of proline derivs.)

RN 292177-85-6 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(1,3-benzodioxol-5-ylacetyl)-N-[2-(diethylamino)ethyl]-4-[[[(2,5-dimethoxyphenyl)amino]carbonyl] [(tetrahydro-2-furanyl)methyl]amino]- (9CI) (CA INDEX NAME)



L14 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:573666 HCAPLUS

DOCUMENT NUMBER: 133:164010

TITLE: Preparation of caprolactams, piperidinones, and pyrrolidinones as Factor Xa inhibitors in prevention or treatment of thromboses, coronary artery disease, or cerebrovascular disease in mammals

INVENTOR(S): Stein, Philip D.; Bisacchi, Gregory S.; Shi, Yan; O'Connor, Stephen P.; Li, Chi

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 284 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047207	A1	20000817	WO 2000-US2883	20000202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2360305	AA	20000817	CA 2000-2360305	20000202
US 6297233	B1	20011002	US 2000-496571	20000202
EP 1156803	A1	20011128	EP 2000-914505	20000202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				



RN 288077-27-0 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(cyanoamino)[(3-methylphenyl)amino]methylene]amino]hexahydro-2-oxo-1H-azepin-1-yl]acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 288077-31-6 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(cyanoamino)[(2-methyl-5-benzofuranyl)amino]methylene]amino]hexahydro-2-oxo-1H-azepin-1-yl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IE, SI, LT, LV, FI, RO
 AU 760174 B2 20030508 AU 2000-35887 20000202
 PRIORITY APPLN. INFO.: US 1999-119372P P 19990209
 US 1999-167428P P 19991124
 WO 2000-US2883 W 20000202
 OTHER SOURCE(S): MARPAT 133:164010
 GI



AB Title chiral compds. [I; R = CN, CONH₂, COOCH₂CH₃, COC₆H₅, SO₂NH₂, OCH₃, SO₂N(CH₃)₂, SO₂CH₃, arylsulfonyl, heterocyclosulfonyl, (un)substituted Ph, heterocyclyl, heterocycleocarbonyl, alkoxylcarbonyl, arylaminocarbonyl; R₁ = H, arylalkyl; R₂ = alkyl, (un)substituted Ph, benzoheterocyclyl, cyclopentyl; R₃ = heterocyclylamino, heterocyclyl, alkoxy, cycloalkylamino, OH; n = 0, 1, 2], pharmaceutically acceptable salts, and stereoisomers are pred. as Factor Xa inhibitors and are useful as anticoagulants (no data). A method for treating cardiovascular diseases associated with thromboses is also provided. Thus, the title compound II was prepared


IT 288077-07-6P 288077-27-0P 288077-31-6P
 288082-99-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of caprolactams as Factor Xa inhibitors in prevention or treatment of thromboses, coronary artery disease, or cerebrovascular disease in mammals)


RN 288077-07-6 HCAPLUS

CN Acetamide, N-[1-[[[(3S)-3-[[[(cyanoamino)[(3-methylphenyl)amino]methylene]amino]hexahydro-2-oxo-1H-azepin-1-yl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 288082-99-5 HCAPLUS
 CN Acetamide, N-[1-[[3-[[[(cyanoamino)[(2-methyl-5-benzofuranyl)amino]methylene]amino]hexahydro-2-oxo-1H-azepin-1-yl]acetyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:473143 HCAPLUS
 DOCUMENT NUMBER: 133:252260
 TITLE: Solid-Phase Synthesis of a Heterocyclic
 Ethylenediamine-Derivatized Library
 AUTHOR(S): Jefferson, Elizabeth A.; Sprankle, Kelly G.; Swayze,
 Eric E.
 CORPORATE SOURCE: Ibis Therapeutics A Division of Isis Pharmaceuticals
 Inc., Carlsbad, CA, 92008, USA
 SOURCE: Journal of Combinatorial Chemistry (2000), 2(5),
 441-444
 CODEN: JCCHFF; ISSN: 1520-4766
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:252260
 GI




AB Solid-phase synthesis of heterocyclic ethylenediamine-derivatized compds.
 I (n, m = 0, 1; R1 = SO₂C₆H₄Me-4, COC₆H₄NH₂-3, etc.; R2 = COC₆H₄Me-3, iso-Bu, etc.; R3 = COBn, thymine-1-acetyl, etc.) is described. The library members were screened in high-through-put RNA-targeted assays, but no high-affinity lead compds. were found.

IT 294875-77-7P 294875-79-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of heterocyclic ethylenediamine-derivatized library)


RN 294875-77-7 HCAPLUS

CN 4-Piperidinecarboxamide, N-[2-[[1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-3-pyrrolidinyl][[(1-methylethyl)amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 294875-79-9 HCAPLUS
 CN Pyrazinecarboxamide, N-[1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-3-pyrrolidinyl]-N-[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:31252 HCAPLUS
 Correction of: 1996:713662
 DOCUMENT NUMBER: 130:52706
 Correction of: 126:75200
 TITLE: Synthesis of Nα-(purinyl/pyrimidinyl acetyl)-4-aminoproline diastereomers with potential use in PNA synthesis
 AUTHOR(S): Gangamani, Bargur P.; Kumar, Vaijayanti A.; Ganesh, Krishna N.
 CORPORATE SOURCE: Div. Org. Chem. (Synthesis), Natl. Chem. Lab., Pune, 411008, India
 SOURCE: Tetrahedron (1996), 52(47), 15017-15030
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB This paper describes an approach to introducing conformational constraint and chirality into the peptide nucleic acid (PNA) backbone by bridging the ethylenediamine and glycine components of the same unit by a methylene group which leads to PNA based on 4-aminoprolyl backbone with chirality at C-4 and C-2. The synthesis and characterization of all four diastereoisomers of I (R = H, Cbz, Fmoc; R1 = H, Me; B = thymine or T) and the synthesis of four compds. of I (R = Boc; R1 = H, CH2Ph; B = thymine,

cytosine, adenine and guanine) with (2S, 4R) stereochem. are described. Using these monomeric units, two model dimers II (R = H, Cbz; B = T) and III (R = H, Fmoc; B = T) containing four chiral centers but differing in stereochem. at only one site were prepared, and CD data on these indicate considerable structural differences in base stacking induced by chiral backbone among these.

IT 185304-38-5P 185304-39-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N α -(purinyl/pyrimidinyl acetyl)aminoproline diastereomers as building blocks for PNA synthesis)

RN 185304-38-5 HCAPLUS

CN L-Proline, 1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4-[[[(2S,4S)-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4-[[phenylmethoxy)carbonyl]amino]-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 185304-39-6 HCAPLUS


CN L-Proline, 1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4-[[[(2R,4S)-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4-[[9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 185304-34-1P 185304-36-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of N α -(purinyl/pyrimidinyl acetyl)aminoproline
 diastereomers as building blocks for PNA synthesis)
 RN 185304-34-1 HCAPLUS
 CN L-Proline, 4-[[[(2S,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-
 pyrimidinyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]-1-[(3,4-dihydro-5-
 methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-, methyl ester, (4S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 185304-36-3 HCAPLUS
 CN L-Proline, 4-[[[(2R,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-
 pyrimidinyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]-1-[(3,4-dihydro-5-
 methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-, methyl ester, (4S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:24087 HCAPLUS

DOCUMENT NUMBER: 130:168639

TITLE: Chiral analogs of peptide nucleic acids: synthesis of 4-aminopropyl nucleic acids and DNA complementation studies using UV/CD spectroscopy

AUTHOR(S): Gangamani, Bargur P.; Kumar, Vaijayanti A.; Ganesh, Krishna N.

CORPORATE SOURCE: Division of Organic Chemistry (Synthesis), National Chemical Laboratory, Pune, 411008, India

SOURCE: Tetrahedron (1999), 55(1), 177-192

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This paper describes chemical synthesis of prolyl peptide nucleic acids (PNAs) which are a class of conformationally constrained chiral PNA analogs. The monomers are derived from bridging the ethylenediamine and glycine components of the same unit which leads to PNA based on 4-aminoproline backbone with chirality at C-4 and C-2. The modified monomers corresponding to D-trans and L-trans prolyl-thymidine have been incorporated into standard PNA chains, both at the N-terminus and in the interior to generate chiral PNAs. The complementation studies with DNA employing temperature dependent UV spectroscopy indicated that the chiral modifications in PNA:DNA duplexes imparted both stability and orientational preferences. CD spectral studies of chiral PNA:DNA duplexes suggest that the D-trans antiparallel duplexes have the B-DNA conformation while L-trans PNA:DNA duplexes show departure from B-DNA geometry. Thus, inclusion of even a single backbone constrained, distended chiral monomeric unit such as 4-aminoproline into an achiral PNA chain, either at the N-terminus or in the interior, leads to stabilization of the PNA:DNA hybrid. The linking of a polycation such as spermine at the C-terminus of chiral PNA further enhances the thermal stability of duplexes.

IT 220259-16-5P 220259-17-6P 220259-18-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and DNA complexation of aminoproline-containing peptide nucleic acids by UV and CD)


RN 220259-16-5 HCAPLUS

CN β -Alanine, (4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-L-prolyl-(2S,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2S,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2S,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2S,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 220259-17-6 HCAPLUS


CN β -Alanine, (4R)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-L-prolyl-(2S,4R)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2S,4R)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2S,4R)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2S,4R)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2S,4R)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 220259-18-7 HCAPLUS
 CN β -Alanine, (4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-D-prolyl-(2R,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2R,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-

pyrrolidinecarbonyl-(2R,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2R,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl-(2R,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinecarbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1997:219832 HCAPLUS
 DOCUMENT NUMBER: 126:305772
 TITLE: New hetero-oligomeric peptide nucleic acids with improved binding properties to complementary DNA
 AUTHOR(S): Jordan, Stephan; Schwemler, Christoph; Kosch, Winfried; Kretschmer, Axel; Stropp, Udo; Schwenner, Eckhardt; Mielke, Burkhard
 CORPORATE SOURCE: Bayer AG, Central Research, Leverkusen, D-51368, Germany
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(6), 687-690
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Hetero-oligomeric PNAs consisting of new monomeric building blocks L-trans-I, L-cis-I, D-trans-I, II, and III (X = O) and various amts. of N-(2-aminoethyl)glycine (IV) have been synthesized by solid-phase chemical Some of these new compds. show stronger binding to complementary DNA than the original PNAs, and are consequently very interesting candidates as antisense compds. for applications in therapy and in diagnostics.
 IT 176230-60-7P 176483-95-7P 189253-82-5P
 189253-83-6P 189253-84-7P 189253-85-8P

189253-87-0P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)


(preparation of new hetero-oligomeric peptide nucleic acids with improved binding properties to complementary DNA)

RN 176230-60-7 HCAPLUS


CN Peptide nucleic acid, (H-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T)-Lys-NH₂ (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-B



PAGE 2-C




RN 176483-95-7 HCAPLUS


CN Peptide nucleic acid, (H-T-[(4S)-Pro]T-T-[(4S)-Pro]T-T-[(4S)-Pro]T-T-[(4S)-Pro]T)-Lys-NH₂ (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-B



PAGE 2-C




RN 189253-82-5 HCAPLUS


CN Peptide nucleic acid, (H-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T)-Lys-NH2 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B




RN 189253-83-6 HCAPLUS


CN Peptide nucleic acid, (H-T-[(4R)-Pro]T-[(4R)-Pro]T-T-[(4R)-Pro]T-[(4R)-Pro]T-T-[(4R)-Pro]T-[(4R)-Pro]T-T-[(4R)-Pro]T-[(4R)-Pro]T-Lys-NH₂ (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-B




PAGE 2-C



PAGE 3-C



PAGE 3-D




RN 189253-84-7 HCAPLUS


CN Peptide nucleic acid, (H-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T)-Lys-NH₂ (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-B





PAGE 2-D




RN 189253-85-8 HCAPLUS


CN Peptide nucleic acid, (H-T-[(4R)-Pro]T-Gly-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-D-Pro-T-[(4R)-Pro]T-Gly-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-D-Pro-T-[(4R)-Pro]T-Gly-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-D-Pro-T-[(4R)-Pro]T-Gly-(4S)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-D-Pro)-Lys-NH₂ (9CI)
(CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A




PAGE 1-B







PAGE 2-B




PAGE 2-C



PAGE 2-D







RN 189253-87-0 HCAPLUS

CN Peptide nucleic acid, (H-T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T)-Lys-NH2 (9CI) (CA INDEX NAME)


Absolute stereochemistry.





PAGE 1-B




PAGE 1-C




PAGE 2-B




PAGE 2-C



PAGE 3-C



PAGE 3-D



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:219831 HCAPLUS

DOCUMENT NUMBER: 126:305771

TITLE: Synthesis of new building blocks for peptide nucleic acids containing monomers with variations in the backbone

AUTHOR(S): Jordan, Stephan; Schwemler, Christoph; Kosch, Winfried; Kretschmer, Axel; Schwenner, Eckhardt; Stropp, Udo; Mielke, Burkhard

CORPORATE SOURCE: Bayer AG, Central Research, Leverkusen, D-51368, Germany

SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(6), 681-686


CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB New PNA monomers, e.g. I (Boc = Me₃CO₂C, B = thymine-1-yl, N⁴-benzyloxycarbonyl-cytosine-1-yl) and both diastereoisomers of II containing aminoprolines or pyrrolidines as backbones have been synthesized. Oligomerization was carried out on a solid support. The oligomers of the new PNA monomers were completely resistance to enzymic degradation. Unfortunately, no hybridization was found for the oligomers with their complementary DNA.


IT 168263-95-4P 189215-96-1P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of new building blocks for peptide nucleic acids containing monomers with variations in the backbone)



RN 168263-95-4 HCAPLUS

CN Peptide nucleic acid, (H-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T)-Ala-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






=O


RN 189215-96-1 HCAPLUS
 CN Peptide nucleic acid, (H-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-[(4R)-Pro]T-Ala-OH (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:713662 HCAPLUS

DOCUMENT NUMBER: 126:75200

TITLE: Synthesis of Na-(purinyl/pyrimidinyl acetyl)-4-aminoproline diastereomers with potential use in PNA synthesis

AUTHOR(S): Gangamani, Bargur P.; Kumar, Vaijayanti A.; Ganesh, Krishna N.

CORPORATE SOURCE: Div. Org. Chemistry (Synthesis), National Chemical lab., Pune, 411008, India

SOURCE: Tetrahedron (1996), 52(47), 15017-15030

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB This paper describes an approach to introducing conformational constraint and chirality into the peptide nucleic acid (PNA) backbone by bridging the ethylenediamine and glycine components of the same unit by a methylene group which leads to PNA based on 4-aminoprolinyl backbone with chirality at C-4 and C-2. The synthesis and characterization of all four diastereoisomers of I (R = H, Cbz, Fmoc; R1 = H, Me; B = thymine or T) and the synthesis of four compds. of I (R = Boc; R1 = H, CH2Ph; B = thymine, cytosine, adenine and guanine) with (2S, 4R) stereochem. are described. Using these monomeric units, two model dimers II (R = H, Cbz; B = T) and III (R = H, Fmoc; B = T) containing four chiral centers but differing in stereochem. at only one site were prepared, and CD data on these indicate considerable structural differences in base stacking induced by chiral backbone among these.

IT 185304-38-5P 185304-39-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of Na-(purinyl/pyrimidinyl acetyl)aminoproline diastereomers as building blocks for PNA synthesis)

RN 185304-38-5 HCAPLUS

CN L-Proline, 1-[[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4-[[[(2S,4S)-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4-[[[(phenylmethoxy)carbonyl]amino]-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 185304-39-6 HCAPLUS

CN L-Proline, 1-[[[(2R,4S)-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 185304-34-1P 185304-36-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of N α -(purinyl/pyrimidinyl acetyl)aminoproline
diastereomers as building blocks for PNA synthesis)

RN 185304-34-1 HCAPLUS


CN L-Proline, 4-[[[(2S,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-, methyl ester, (4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 185304-36-3 HCAPLUS
 CN L-Proline, 4-[[[(2R,4S)-4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-, methyl ester, (4S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.




REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:440544 HCAPLUS
 DOCUMENT NUMBER: 125:114472
 TITLE: Preparation of pyrrolidinecarboxylic acid derivatives as angiotensin II antagonists.
 INVENTOR(S): Yanagisawa, Hiroaki; Kanazaki, Takuo; Amamya, Yosha; Furusawa, Juji; Mizuno, Makoto
 PATENT ASSIGNEE(S): Sankyo Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 259 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08092207	A2	19960409	JP 1995-189453	19950725
PRIORITY APPLN. INFO.:			JP 1995-189453	A 19950725
			JP 1994-174452	19940726
OTHER SOURCE(S):	MARPAT 125:114472			
GI				



I



II

AB The title compds. [I; R1 = C1-6 alkyl, C2-6 alkenyl; R2 = (un)substituted C1-6 alkyl, C3-6 alkenyl or alkynyl, C3-6 cycloalkyl, etc.; R3 = H, protecting group; R4 = (protected) CO2H, tetrazolyl, SO2NHCOR5 (wherein R5 = C1-16 alkyl, C6-14 aryl; Y = O, bond), (un)substituted Ph; X = bond, O; Z1, Z2 = CO, SO2], useful as cardiovascular agents in treating hypertension, etc., at 0.5-30 mg/day in adults, are prepared. Acylation of trityl compound (2S,4S)-II (R = trityl, R3 = Me, R5 = H) with (BuCO)2O in pyridine gave valeryl compound (2S,4S)-II (R = trityl, R3 = Me, R5 = BuCO), which was treated with HOAc to give (2S,4S)-II (R = H, R3 = Me, R5 = BuCO) (III). Saponification of III gave the free acid II (R = R3 = H, R5 = BuCO).

IC50

of I against angiotensin II in rats were determined

IT 178866-66-5P 178866-67-6P 178866-68-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidinecarboxylic acid derivs. as angiotensin II antagonists.)

RN 178866-66-5 HCAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-1-(4-pyridinylacetyl)-, monohydrochloride, cis- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 178866-67-6 HCAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-1-(3-pyridinylacetyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-68-7 HCAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-1-(2-pyridinylacetyl)-, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 178867-99-7P 178868-00-3P 178868-02-5P

178868-03-6P 178868-05-8P 178868-06-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation of pyrrolidinecarboxylic acid derivs. as angiotensin II antagonists.)

RN 178867-99-7 HCAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]-1-(4-pyridinylacetyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-00-3 HCAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-1-(4-pyridinylacetyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-02-5 HCAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]-1-(3-pyridinylacetyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-03-6 HCAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-1-(3-pyridinylacetyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-05-8 HCAPLUS


CN L-Proline, 4-[(1-oxobutyl)[[2'-(1-(triphenylmethyl)-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-1-(2-pyridinylacetyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178868-06-9 HCAPLUS
 CN L-Proline, 4-[(1-oxobutyl)[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]amino]-1-(2-pyridinylacetyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:281618 HCAPLUS
 DOCUMENT NUMBER: 124:344113
 TITLE: Preparation of nucleic acid-binding oligomers as drugs and diagnostic agents.
 INVENTOR(S): Schwemler, Christoph; Poetter, Thorsten; Mielke, Burkhard; Schwenner, Eckhard; Kretschmer, Axel; Stropp, Udo; Kosch, Winfried; Duerr, Hanshoerg
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4427980	A1	19960215	DE 1994-4427980	19940808
EP 700928	A1	19960313	EP 1995-111735	19950726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
AU 9528321	A1	19960222	AU 1995-28321	19950801
US 5955571	A	19990921	US 1995-509913	19950801
JP 08059692	A2	19960305	JP 1995-216573	19950803
CA 2155496	AA	19960209	CA 1995-2155496	19950804

PRIORITY APPLN. INFO.: DE 1994-4427980 A 19940808

AB M[NHGAN[D(CH2)mB]K[QCH2CH2N(COCH2B)CH2CO]r]sL [A = (CH2)n, CO; B = (un)natural nucleobase (deriv); D = (CO)p; E, G = CHR; R = H, (protected) amino acid residue; E and G may be connected by a (substituted) alkylene chain; K = CO, SO2, CH2; L = H, carrier system, reporter ligand, solubilizing group; Q = NH, O, S, NR; m = 0-3; n = 0-4; p = 0-2; r = 0, 1; s = 1-30], were prepared Thus, H-T1-T2-T1-T2-T1-T2-T1-T2-Lys-NH2 [T1 = aminoethylglycine thymine residue; T2 = L-trans-4-amino-N-[(thymine-1-yl)acetyl]proline residue], prepared by solid phase synthesis using BOC methodol. on MBHA resin, was stable to proteinase K and S1 nuclease while hybridizing very strongly with single stranded DNA.

IT 176230-60-7P 176483-95-7P

Pryor 10_797927


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nucleic acid-binding oligomers as drugs and diagnostic agents)

RN 176230-60-7 HCAPLUS


CN Peptide nucleic acid, (H-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T-T-[(4R)-Pro]T)-Lys-NH₂ (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-B




PAGE 2-C




RN 176483-95-7 HCAPLUS
 CN Peptide nucleic acid, (H-T-[(4S)-Pro]T-T-[(4S)-Pro]T-T-[(4S)-Pro]T-T-[(4S)-Pro]T)-Lys-NH₂ (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-B




PAGE 2-C



L14 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1995:820572 HCAPLUS
 DOCUMENT NUMBER: 123:228912
 TITLE: Preparation of nucleic acid-binding oligomers with amino acid-containing backbones and nucleobase-containing side chains.
 INVENTOR(S): Loebberding, Antonius; Mielkde, Burkhard; Schwemler, Christoph; Schwenner, Eckhardt; Stropp, Udo; Springer, Wolfgang; Kretschmer, Axel; Poetter, Thorsten
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 23 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4331012	A1	19950316	DE 1993-4331012	19930913
AU 9471543	A1	19950323	AU 1994-71543	19940829
AU 676349	B2	19970306		
EP 646595	A1	19950405	EP 1994-113569	19940831
EP 646595	B1	19981104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, SE				
AT 172984	E	19981115	AT 1994-113569	19940831

ES 2124345	T3	19990201	ES 1994-113569	19940831
US 5623049	A	19970422	US 1994-300884	19940906
JP 07118243	A2	19950509	JP 1994-239644	19940908
CA 2131755	AA	19950314	CA 1994-2131755	19940909
PRIORITY APPLN. INFO.:			DE 1993-4331012	A 19930913
OTHER SOURCE(S):	MARPAT	123:228912		
GI				



AB Title compds. [I; A = (CH₂)_n, CO; B = (un)natural nucleoside base; D = (CO)_p; E, G = CHR; R = H, (un)natural amino acid residue; E and G may be bonded to each other by (CH₂)_n; K = CO, SO₂, CH₂; M, L = H, carrier system, reporter ligand, solubilizing group; m = 0-3; n = 0-4; p, q = 0-2; s = 1-30], were prepared. Thus, H-(Q1)-8-Ala-OH, prepared by solid phase synthesis on phenylacetamidomethyl resin, showed concentration-dependent and sequence-selective binding to double-stranded DNA and showed stability to various proteases.

IT 168263-94-3P 168263-95-4P 168263-96-5P
168263-97-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleic acid-binding oligomers with amino acid-containing backbones and nucleobase-containing side chains)

RN 168263-94-3 HCAPLUS

CN L-Alanine, N-[cis-4-[[[4-amino-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-L-prolyl]-, (2S-cis)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 168263-95-4 HCAPLUS


CN Peptide nucleic acid, (H-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T)-Ala-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 2-C




RN 168263-96-5 HCAPLUS


CN Peptide nucleic acid, (H-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-(Pro)T-Ala-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



Pryor 10_797927..

PAGE 1-C






PAGE 2-A




Me




PAGE 2-B




PAGE 2-C





RN 168263-97-6 HCAPLUS
 CN L-Alanine, N-[cis-4-[[[4-amino-1-[(4-amino-2-oxo-1(2H)-pyrimidin-5-yl)acetyl]-2-pyrrolidinyl]carbonyl]amino]-1-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidin-2-yl)acetyl]-L-prolyl]-, (2S-cis)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L14 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:680647 HCAPLUS
 DOCUMENT NUMBER: 121:280647
 TITLE: Preparation of [(tetrazolylbiphenyl)methyl]imidazo[4,5-c]pyridines and related compounds as angiotensin II antagonists
 INVENTOR(S): Mederski, Werner; Dorsch, Dieter; Osswald, Mathias; Beier, Norbert; Schelling, Pierre; Lues, Ingeborg; Minck, Klaus Otto
 PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 574846	A2	19931222	EP 1993-109410	19930611

EP 574846	A3	19940706		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4305602	A1	19931223	DE 1993-4305602	19930224
AU 9341238	A1	19931223	AU 1993-41238	19930611
AU 669895	B2	19960627		
CZ 283081	B6	19971217	CZ 1993-1145	19930611
CA 2098473	AA	19931218	CA 1993-2098473	19930615
NO 9302218	A	19931220	NO 1993-2218	19930616
ZA 9304289	A	19940117	ZA 1993-4289	19930616
CN 1082545	A	19940223	CN 1993-107194	19930617
CN 1038511	B	19980527		
HU 64761	A2	19940228	HU 1993-1766	19930617
JP 06056832	A2	19940301	JP 1993-146312	19930617
US 5476857	A	19951219	US 1993-77592	19930617
PL 173777	B1	19980430	PL 1993-299368	19930617
PRIORITY APPLN. INFO.:			DE 1992-4219818	A 19920617
			DE 1993-4305602	A 19930224
OTHER SOURCE(S):		MARPAT 121:280647		
GI				




AB Title compds. [I; R1 = alkyl, alkenyl, alkynyl, cycloalkylalkyl, etc.; R2 = H, CO₂H, alkoxy carbonyl, cyano, NO₂, acylamino, 1H-tetrazol-5-yl; R3 = substituted alkenyl, etc.; R4 = H, halo; X = null, NHCO, OCH(CO₂H), NHCH(CO₂H), CH:C(CO₂H), CH:C(CN), etc.; Y = O, S], were prepared as angiotensin II antagonists (no data). Thus, valeric acid and 4-amino-1,2-dihydro-2-oxo-3-[2'-(1H-5-tetrazolyl)biphenyl-4-methylamino]-1-(N,N-dimethylcarbamoylmethyl)pyridine (preparation given) were heated 5 h in polyphosphoric acid at 140° to give 2-butyl-4,5-dihydro-5-(N,N-dimethylcarbamoylmethyl)-4-oxo-3-[2'-(1H-5-tetrazolyl)biphenyl-4-methyl]-3H-imidazo[4,5-c]pyridine. Generic I drug formulations are given.


IT 158938-85-3P 158938-90-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as angiotensin II antagonist)

RN 158938-85-3 HCAPLUS


CN Acetamide, N-[1-[[3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-2-ethyl-3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-3-pyrrolidinyl]- (9CI)
 (CA INDEX NAME)



RN 158938-90-0 HCAPLUS
 CN Acetamide, N-[1-[[2-ethyl-3,4-dihydro-4-oxo-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




=> => d stat que 129
 L1 STR



VAR G1=AK/CY/18
 VAR G2=CH2/N
 REP G3=(1-2) CH2
 REP G4=(0-1) CH2
 NODE ATTRIBUTES:
 NSPEC IS RC AT 18
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
 L3 857 SEA FILE=REGISTRY SSS FUL L1
 L4 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L3
 L10 STR



N@18

VAR G1=AK/CY/18

VAR G2=CH2/N

NODE ATTRIBUTES:

NSPEC IS RC AT 18

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

```

L11      915 SEA FILE=REGISTRY SSS FUL L10
L12      58 SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT L3
L13      22 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
L14      22 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 NOT L4
L15      47 SEA FILE=HCAPLUS ABB=ON PLU=ON ("GOODFELLOW V"/AU OR
      "GOODFELLOW V J"/AU OR "GOODFELLOW V S"/AU OR "GOODFELLOW
      VAL"/AU OR "GOODFELLOW VAL S"/AU OR "GOODFELLOW VAL SMITH"/AU
      OR "GOODFELLOW VALERIE"/AU OR "GOODFELLOW VALERIE J"/AU)
L16      22 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ROWBOTTOM MARTIN"/AU OR
      "ROWBOTTOM MARTIN W"/AU)
L17      35 SEA FILE=HCAPLUS ABB=ON PLU=ON "DYCK B"/AU OR ("DYCK
      BRIAN"/AU OR "DYCK BRIAN P"/AU OR "DYCK BRIAN PETER"/AU)
L18      14 SEA FILE=HCAPLUS ABB=ON PLU=ON "TAMIYA JUNKO"/AU
L19      432 SEA FILE=HCAPLUS ABB=ON PLU=ON ZHANG M ?/AU OR "ZHANG
      MINGZHU"/AU
L20      35 SEA FILE=HCAPLUS ABB=ON PLU=ON GREY J ?/AU OR "GREY JONATHAN"
      /AU
L21      12 SEA FILE=HCAPLUS ABB=ON PLU=ON "VICKERS T"/AU OR ("VICKERS
      TROY"/AU OR "VICKERS TROY D"/AU)
L22      7 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND L16 AND L17 AND L18
      AND L19 AND L20 AND L21
L23      16 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR
      L19 OR L20 OR L21)
L24      9 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19 OR
      L20 OR L21)
L25      10 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19 OR L20 OR
      L21)
L26      8 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (L19 OR L20 OR L21)
L27      7 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 AND (L20 OR L21)
L28      7 SEA FILE=HCAPLUS ABB=ON PLU=ON L20 AND L21
L29      14 SEA FILE=HCAPLUS ABB=ON PLU=ON (L22 OR L23 OR L24 OR L25 OR
      L26 OR L27 OR L28) NOT (L4 OR L14)

```

=>

=>

=> d ibib abs 129 1-14

L29 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:830343 HCAPLUS
 TITLE: Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2
 AUTHOR(S): Hudson, Sarah; Kiankarimi, Mehrak; Rowbottom, Martin W.; Vickers, Troy D.; Wu, Dongpei; Pontillo, Joseph; Ching, Brett; Dwight, Wesley; Goodfellow, Val S.; Schwarz, David; Heise, Christopher E.; Madan, Ajay; Wen, Jenny; Ban, William; Wang, Hua; Wade, Warren S.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences Inc., 12790 El Camino Real, San Diego, CA, 92130, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(18), 4922-4930
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compds. from this series exhibited considerable binding affinity ($K_i = 1$ nM) and functional activity at MCH-R1, acceptable CYP2D6 inhibition, and good rat brain exposure.

L29 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:757644 HCAPLUS
 TITLE: Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1
 AUTHOR(S): Rowbottom, Martin W.; Vickers, Troy D.; Dyck, Brian; Grey, Jonathan; Tamiya, Junko; Zhang, Mingzhu; Kiankarimi, Mehrak; Wu, Dongpei; Dwight, Wesley; Wade, Warren S.; Schwarz, David; Heise, Christopher E.; Madan, Ajay; Fisher, Andrew; Petroski, Robert; Goodfellow, Val S.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences Inc., San Diego, CA, 92130, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(17), 4450-4457
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compds. from this series exhibited potent binding affinity and functional activity at MCH-R1, and good oral bioavailability in rat.
 REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:693841 HCAPLUS
 TITLE: Substituted chromones and quinolones as potent

AUTHOR(S): melanin-concentrating hormone receptor 1 antagonists
Dyck, Brian; Zhao, Liren; Tamiya, Junko; Pontillo, Joseph; Hudson, Sarah; Ching, Brett; Heise, Christopher E.; Wen, Jenny; Norton, Christi; Madan, Ajay; Schwarz, David; Wade, Warren; Goodfellow, Val S.

CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92130, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(16), 4237-4242
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of substituted chromones were designed, synthesized, and evaluated for their ability to bind melanin-concentrating hormone receptor 1. Compds. with subnanomolar binding affinity and 66% oral bioavailability in rats were discovered.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:506376 HCAPLUS

DOCUMENT NUMBER: 145:116713

TITLE: A Thienopyridazinone-Based Melanin-Concentrating Hormone Receptor 1 Antagonist with Potent in Vivo Anorectic Properties

AUTHOR(S): Dyck, Brian; Markison, Stacy; Zhao, Liren; Tamiya, Junko; Grey, Jonathan; Rowbottom, Martin W.; Zhang, Mingzhu; Vickers, Troy; Sorensen, Katie; Norton, Christi; Wen, Jenny; Heise, Christopher E.; Saunders, John; Conlon, Paul; Madan, Ajay; Schwarz, David; Goodfellow, Val S.

CORPORATE SOURCE: Neurocrine Biosciences Inc., San Diego, CA, 92130, USA

SOURCE: Journal of Medicinal Chemistry (2006), 49(13), 3753-3756
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Melanin-concentrating hormone receptor antagonists containing thieno- and a benzopyridazinone cores were designed and tested as potential anorectic agents. These ligands showed high affinity for the receptor, potent functional activity in vitro, and good oral bioavailability in rats. The thiophene analog exhibited low iv clearance, long half-life, and high brain penetration. In obese rats, the thienopyridazinone demonstrated a dose-dependent reduction in feeding and body weight with doses between 1 and 10 mg kg⁻¹.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1170336 HCAPLUS

DOCUMENT NUMBER: 143:440267

TITLE: Preparation of aminopyrrolidinyl pyridines as MCH receptor antagonists

INVENTOR(S): Goodfellow, Val; Dyck, Brian P.; Zhao, Liren; Tamiya, Junko; Grey,

PATENT ASSIGNEE(S): Jonathan; Wade, Warren; Rowbottom, Martin
 SOURCE: ; Zhang, Mingzhu; Vickers, Troy D.
 Neurocrine Biosciences, Inc., USA
 PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103039	A1	20051103	WO 2005-US12853	20050415
WO 2005103039	C1	20060511		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2005256124 A1 20051117 US 2005-107317 20050415 PRIORITY APPLN. INFO.: US 2004-562389P P 20040415 OTHER SOURCE(S): MARPAT 143:440267 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, (un)substituted alkyl, aryl, etc.; R2 = H, C(O)R4, (un)substituted alkyl, etc. or R1 and R2 together may form (un)substituted heterocycle; R3 = H, CN, halo, etc.; R4 = OH, (un)substituted -O-alkyl, arylalkyl, etc.; Het = mono- or bicyclic (un)substituted heterocycle containing 1-3 heteroatoms selected from O, S or N and containing a keto functionality that is adjacent to the carbon which the pyridyl ring is attached to; X = a bond or O; Cyc = (un)substituted cycloalkyl, aryl or heterocycle] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of MCH receptor. Thus, e.g., II was prepared by reduction of 4-bromophthalimide followed by treatment with hydrazine to give the resp. bromophthalazinone, which underwent a palladium catalyzed Suzuki coupling with 4-(trifluoromethyl)phenylboronic acid and subsequent coupling with III (preparation given). Assay methods for evaluation of binding ability of I to MCH receptors are described (no data). I as MCH receptor antagonist should prove useful in the treatment of obesity, depression and fertility dysfunction. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:921450 HCAPLUS
 DOCUMENT NUMBER: 143:405877
 TITLE: Potent and orally active non-peptide antagonists of

the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines

AUTHOR(S): Tucci, Fabio C.; White, Nicole S.; Markison, Stacy; Joppa, Margaret; Tran, Joe A.; Fleck, Beth A.; Madan, Ajay; Dyck, Brian P.; Parker, Jessica; Pontillo, Joseph; Melissa Arellano, L.; Marinkovic, Dragan; Jiang, Wanlong; Chen, Caroline W.; Gogas, Kathleen R.; Goodfellow, Val S.; Saunders, John; Foster, Alan C.; Chen, Chen

CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences Inc., San Diego, CA, 92130, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(19), 4389-4395
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The melanocortin-4 receptor (MC4R) plays an important role in the regulation of energy homeostasis. Recent studies have shown that blockade of the MC4R reverses tumor-induced weight loss in mice. Herein, the synthesis and identification of potent and selective non-peptide antagonists of the human MC4R from a series of 2-[(ethoxycarbonyl)cyclohexyl]piperazine derivs. are described. One compds. was found to possess low nanomolar affinity for the MC4R, and exhibit oral bioavailability in rats. More importantly, when administered orally to mice (10 mg/kg), it led to statistically significant increases in food intake over a 24-h period.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:636156 HCAPLUS

DOCUMENT NUMBER: 143:241362

TITLE: 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists

AUTHOR(S): Huang, Charles Q.; Baker, Tracy; Schwarz, David; Fan, Jun; Heise, Christopher E.; Zhang, Mingzhu; Goodfellow, Val S.; Markison, Stacy; Gogas, Kathleen R.; Chen, Takung; Wang, Xiao-Chuan; Zhu, Yun-Fei

CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, CA, 92130, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(16), 3701-3706
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Derivs. of 1-(4-amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine were identified as potent and functionally active MCH-R1 antagonists. One compound with $K_i = 2.3$ nM demonstrated good oral bioavailability (32%) and in vivo efficacy in rats.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:601101 HCAPLUS

DOCUMENT NUMBER: 143:266895

TITLE: Design and Synthesis of Tricyclic Imidazo[4,5-b]pyridin-2-ones as Corticotropin-Releasing Factor-1 Antagonists

AUTHOR(S): Guo, Zhiqiang; Tellew, John E.; Gross, Raymond S.; Dyck, Brian; Grey, Jonathan; Haddach, Mustapha; Kiankarimi, Mehrak; Lanier, Marion; Li, Bin-Feng; Luo, Zhiyong; McCarthy, James R.; Moorjani, Manisha; Saunders, John; Sullivan, Robert; Zhang, Xiaohu; Zamani-Kord, Said; Grigoriadis, Dimitri E.; Crowe, Paul D.; Chen, Ta Kung; Williams, John P.

CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology, and Preclinical Development, Neurocrine Biosciences, Inc., San Diego, CA, 92130, USA

SOURCE: Journal of Medicinal Chemistry (2005), 48(16), 5104-5107

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:266895

AB The synthesis and SAR studies of tricyclic imidazo[4,5-b]pyridin-2-ones as human corticotropin-releasing factor receptor (CRF1) antagonists were discussed. One compound was identified as a functional antagonist that inhibited CRF-stimulated cyclic adenosine monophosphate production and CRF-induced adrenocorticotrophic hormone release. Pharmacokinetics studies in rats showed that this compound was orally bioavailable, had good brain penetration, and had a moderate half-life. In an effort to identify CRF1 antagonists with improved pharmacokinetics properties, this compound also exhibited a favorably lower volume of distribution. Because of the key role CRF plays a role in stress response, centrally acting CRF1 antagonists are expected to be useful in the treatment of stress-related psychiatric disorders, such as anxiety and depression.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:451389 HCAPLUS

DOCUMENT NUMBER: 143:7724

TITLE: A preparation of pyrimidine derivatives, useful as melanin-concentrating hormone receptor antagonists

INVENTOR(S): Goodfellow, Val; Zhang, Mingzhu; Tamiya, Junko

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047293	A1	20050526	WO 2004-US37203	20041105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

US 2005176738 A1 20050811 US 2004-982696 20041105
 PRIORITY APPLN. INFO.: US 2003-518480P P 20031107
 OTHER SOURCE(S): MARPAT 143:7724
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of pyrimidine derivs. of formula I
 [wherein: R1 is H, halogen, CN, alkyl, or arylalkyl, etc.; R2 is H, alkyl,
 aryl, or heterocycle, etc.; R3 is pyrrolidin-3-yl derivs.; X is CH or N; Y
 is S, O, or CH:N, etc.], useful as melanin-concentrating hormone (MCH) receptor
 antagonists (no biol. data). For instance, thienopyrimidine derivative II was
 prepared via amidation of carbamic acid derivative III by
 pyrrolidinylthienopyrimidine derivative IV, N-debenzylation, and N-alkylation
 by 4,4-dimethylcyclohexanone.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:780502 HCAPLUS

DOCUMENT NUMBER: 141:295848

TITLE: Preparation of bis(3-aminopyrrolidin-1-yl)methanones
 as melanin-concentrating hormone receptor antagonists
 for treatment of obesity and other disorders

INVENTOR(S): Goodfellow, Val; Rowbottom, Martin
 ; Dyck, Brian P.; Tamiya, Junko;
 Zhang, Mingzhu; Grey, Jonathan;
 Vickers, Troy; Kiankarimi, Mehrak; Wade,
 Warren; Hudson, Sarah Clough

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080411	A2	20040923	WO 2004-US7260	20040308
WO 2004080411	A3	20041216		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004259931	A1	20041223	US 2004-797487	20040308

US 7067509
 PRIORITY APPLN. INFO.:
 OTHER SOURCE(S):
 GI

B2 20060627
 MARPAT 141:295848

US 2003-452709P P 20030307



AB Title pyrrolidinamines I [wherein $n = 0, 1$; $R_1 = H$, (un)substituted (aryl)alkyl, heterocyclyl(alkyl); $R_2 = H$, (un)substituted alkyl, COR7, SO2R8; or $NR_1R_2 =$ (un)substituted heterocyclyl; $R_3, R_5, R_6, R_8 =$ independently H , (un)substituted alkyl; $R_4 =$ (un)substituted alkyl, (hetero)aryl, heterocyclyl; $R_7 =$ independently H, OH , alkoxy, (un)substituted alkyl, aryl, heterocyclyl; $R_9 = OH$, alkoxy, (un)substituted alkyl, aryl; and stereoisomers, prodrugs, or pharmaceutically acceptable salts thereof] were prepared as melanin-concentrating hormone (MCH) receptor antagonists. For example, a 6-step synthesis starting from (R)-3-amino-1-benzylpyrrolidine, 4-nitrophenyl (S)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate, 4-trifluoromethyl-5-phenylthiophene-2-carboxylic acid, and cycloheptanone gave II. Over half of the exemplified invention compds., including II, exhibited the ability to bind to the human [125I]-MCH receptor with K_i values $< 1 \mu M$. Thus, I and their pharmaceutical compns. are useful for the treatment of MCH receptor-based disorders, such as obesity, anxiety, depression, digestive disorders, fertility, sexual function disorders, and urinary disorders (no data).

L29 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:153570 HCAPLUS

DOCUMENT NUMBER: 140:391240

TITLE: Potent imidazole and triazole CB1 receptor antagonists related to SR141716

AUTHOR(S): Dyck, Brian; Goodfellow, Val S.;
 Phillips, Teresa; Grey, Jonathan; Haddach,
 Mustapha; Rowbottom, Martin; Naeve, Gregory
 S.; Brown, Brock; Saunders, John

CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and
 Molecular Biology, Neurocrine Biosciences Inc., San
 Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),
 14(5), 1151-1154
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:391240
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human CB1 receptor. Suitably substituted imidazoles are comparably potent to the clin. candidate, whereas the analogous triazoles are less so due to the absence of an addnl. substituent on the azole ring. Example compds. thus prepared and evaluated were derivs. of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (SR 141716) (I), such as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(hexahydro-1H-azepin-1-yl)-1H-1,2,4-triazole-3-carboxamide (II) and 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-methyl-1H-imidazole-4-carboxamide (III).

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:795103 HCAPLUS

DOCUMENT NUMBER: 140:52763

TITLE: Aryl piperazine melanocortin MC4 receptor agonists

AUTHOR(S): Dyck, Brian; Parker, Jessica; Phillips, Teresa; Carter, Lee; Murphy, Brian; Summers, Robin; Hermann, Julia; Baker, Tracy; Cismowski, Mary; Saunders, John; Goodfellow, Val

CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology, and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(21), 3793-3796

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:52763

AB Incorporation of substituted Ph piperazine privileged structures into a known MC4 specific dipeptoid consensus sequence resulted in a series of potent (EC50=24 nM) and selective MC4-R agonists. We report the structure-activity relationship (SAR) of this series of compds. using in vitro cAMP functional assays in cells transfected with the MC4 or other melanocortin receptors.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:656738 HCAPLUS


DOCUMENT NUMBER: 139:197359

TITLE: Preparation of pyrroles as ligands of melanocortin receptors

INVENTOR(S): Dyck, Brian P.; Goodfellow, Val; Parker, Jessica; Phillips, Teresa; Wade, Warren; Tran, Joe Anh

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068738	A1	20030821	WO 2003-US4455	20030211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003216274	A1	20030904	AU 2003-216274	20030211
PRIORITY APPLN. INFO.:				
			US 2002-355867P	P 20020211
			WO 2003-US4455	W 20030211
OTHER SOURCE(S): MARPAT 139:197359				
GI				





AB The title compds. [I; A = a bond, NR8; n = 3-6; R1, R2 = H, alkyl, heterocyclyl, etc.; or NR1R2 = (un)substituted heterocyclyl; R31, R32 = H, alkyl, alkoxy, etc.; R4 = carbocyclyl, heterocyclyl, etc.; R5-R7 = H, halo, alkyl, etc.; R8 = H, alkyl, aryl, etc.] which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders (no data given), were prepared E.g., synthesis of II, was described. Table of 487 prepared compds. I was given. Pharmaceutical composition comprising the compound I was claimed.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:301053 HCAPLUS
 DOCUMENT NUMBER: 138:321578

TITLE: Preparation of peptides as ligands of melanocortin receptors
 INVENTOR(S): Dyck, Brian P.; Goodfellow, Val; Phillips, Teresa; Parker, Jessica; Zhang, Xiaohu; Chen, Chen; Tran, Joe Anh; Pontillo, Joseph; Tucci, Fabio C.
 PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031410	A1	20030417	WO 2002-US32282	20021009
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003158209	A1	20030821	US 2002-268923	20021009
EP 1465867	A1	20041013	EP 2002-800985	20021009
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005506338	T2	20050303	JP 2003-534394	20021009
PRIORITY APPLN. INFO.:			US 2001-328295P	P 20011009
			US 2002-366745P	P 20020322
			WO 2002-US32282	W 20021009
OTHER SOURCE(S):	MARPAT 138:321578			
GI				



AB The invention relates to peptides I [$m = 1-4$; $n = 0-4$; A is (un)substituted alkanediyl; $R_1, R_2, R_{3a}, R_{3b} = H$, (un)substituted alkyl, aryl, arylalkyl, heterocyclyl, or heterocyclalkyl or may combine to form rings; R_1 or R_2 may also be acyl; $R_4 =$ (un)substituted (hetero)aryl; $R_5 = H, OH$, (un)substituted alkyl, aryl, or heterocyclyl; $R_6 =$ cyano, nitro, (un)substituted heterocyclyl, amino, carbamoyl, etc.; $R_7 = H$ or 1-4 substituents], or stereoisomers, prodrugs or pharmaceutically-acceptable salts, which function as melanocortin receptor ligands and may be used to treat disorders or illnesses including cachexia, obesity, diabetes, inflammation, and sexual dysfunction. Thus, treatment of cyclohexanone with sodium metabisulfite in H_2O , followed by addition of Boc-protected piperazine and then $NaCN$, afforded 1-Boc-4-(1-cyanocyclohexyl)piperazine. The latter was converted into peptide II via coupling reaction.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d stat que 132
L1 STR




VAR G1=AK/CY/18
VAR G2=CH2/N
REP G3=(1-2) CH2
REP G4=(0-1) CH2
NODE ATTRIBUTES:
NSPEC IS RC AT 18

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L3 857 SEA FILE=REGISTRY SSS FUL L1
L4 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L3
L10 STR



VAR G1=AK/CY/18
VAR G2=CH2/N
NODE ATTRIBUTES:
NSPEC IS RC AT 18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L11 915 SEA FILE=REGISTRY SSS FUL L10
L12 58 SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT L3
L13 22 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
L14 22 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 NOT L4
L15 47 SEA FILE=HCAPLUS ABB=ON PLU=ON ("GOODFELLOW V"/AU OR
"GOODFELLOW V J"/AU OR "GOODFELLOW V S"/AU OR "GOODFELLOW
VAL"/AU OR "GOODFELLOW VAL S"/AU OR "GOODFELLOW VAL SMITH"/AU
OR "GOODFELLOW VALERIE"/AU OR "GOODFELLOW VALERIE J"/AU)
L16 22 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ROWBOTTOM MARTIN"/AU OR
"ROWBOTTOM MARTIN W"/AU)
L17 35 SEA FILE=HCAPLUS ABB=ON PLU=ON "DYCK B"/AU OR ("DYCK
BRIAN"/AU OR "DYCK BRIAN P"/AU OR "DYCK BRIAN PETER"/AU)
L18 14 SEA FILE=HCAPLUS ABB=ON PLU=ON "TAMIYA JUNKO"/AU
L19 432 SEA FILE=HCAPLUS ABB=ON PLU=ON ZHANG M ?/AU OR "ZHANG
MINGZHU"/AU
L20 35 SEA FILE=HCAPLUS ABB=ON PLU=ON GREY J ?/AU OR "GREY JONATHAN"
/AU
L21 12 SEA FILE=HCAPLUS ABB=ON PLU=ON "VICKERS T"/AU OR ("VICKERS
TROY"/AU OR "VICKERS TROY D"/AU)
L22 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND L16 AND L17 AND L18
AND L19 AND L20 AND L21
L23 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR
L19 OR L20 OR L21)
L24 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19 OR
L20 OR L21)

L25 10 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19 OR L20 OR L21)
 L26 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (L19 OR L20 OR L21)
 L27 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 AND (L20 OR L21)
 L28 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L20 AND L21
 L30 436 SEA FILE=REGISTRY ABB=ON PLU=ON MELANIN
 L31 11785 SEA FILE=HCAPLUS ABB=ON PLU=ON L30 OR MELANIN
 L32 8 SEA FILE=HCAPLUS ABB=ON PLU=ON ((L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28) AND L31) NOT (L4 OR L14)

=> d ibib abs l32 1-8

L32 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:830343 HCAPLUS
 TITLE: Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin -concentrating hormone receptor-1 (MCH-R1). Part 2
 AUTHOR(S): Hudson, Sarah; Kiankarimi, Mehrak; Rowbottom, Martin W.; Vickers, Troy D.; Wu, Dongpei; Pontillo, Joseph; Ching, Brett; Dwight, Wesley; Goodfellow, Val S.; Schwarz, David; Heise, Christopher E.; Madan, Ajay; Wen, Jenny; Ban, William; Wang, Hua; Wade, Warren S.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences Inc., 12790 El Camino Real, San Diego, CA, 92130, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(18), 4922-4930
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compds. from this series exhibited considerable binding affinity ($K_i = 1$ nM) and functional activity at MCH-R1, acceptable CYP2D6 inhibition, and good rat brain exposure.

L32 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:757644 HCAPLUS
 TITLE: Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin -concentrating hormone receptor-1 (MCH-R1). Part 1
 AUTHOR(S): Rowbottom, Martin W.; Vickers, Troy D.; Dyck, Brian; Grey, Jonathan; Tamiya, Junko; Zhang, Mingzhu; Kiankarimi, Mehrak; Wu, Dongpei; Dwight, Wesley; Wade, Warren S.; Schwarz, David; Heise, Christopher E.; Madan, Ajay; Fisher, Andrew; Petroski, Robert; Goodfellow, Val S.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences Inc., San Diego, CA, 92130, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(17), 4450-4457
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compds. from this series exhibited potent binding affinity and functional activity at MCH-R1, and good oral bioavailability in rat.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:693841 HCAPLUS

TITLE: Substituted chromones and quinolones as potent melanin-concentrating hormone receptor 1 antagonists

AUTHOR(S): Dyck, Brian; Zhao, Liren; Tamiya, Junko; Pontillo, Joseph; Hudson, Sarah; Ching, Brett; Heise, Christopher E.; Wen, Jenny; Norton, Christi; Madan, Ajay; Schwarz, David; Wade, Warren; Goodfellow, Val S.

CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92130, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(16), 4237-4242

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of substituted chromones were designed, synthesized, and evaluated for their ability to bind melanin-concentrating hormone receptor 1. Compds. with subnanomolar binding affinity and 66% oral bioavailability in rats were discovered.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:506376 HCAPLUS

DOCUMENT NUMBER: 145:116713

TITLE: A Thienopyridazinone-Based Melanin -Concentrating Hormone Receptor 1 Antagonist with Potent in Vivo Anorectic Properties

AUTHOR(S): Dyck, Brian; Markison, Stacy; Zhao, Liren; Tamiya, Junko; Grey, Jonathan; Rowbottom, Martin W.; Zhang, Mingzhu; Vickers, Troy; Sorensen, Katie; Norton, Christi; Wen, Jenny; Heise, Christopher E.; Saunders, John; Conlon, Paul; Madan, Ajay; Schwarz, David; Goodfellow, Val S.

CORPORATE SOURCE: Neurocrine Biosciences Inc., San Diego, CA, 92130, USA

SOURCE: Journal of Medicinal Chemistry (2006), 49(13), 3753-3756

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Melanin-concentrating hormone receptor antagonists containing thieno- and a benzopyridazinone cores were designed and tested as potential anorectic agents. These ligands showed high affinity for the receptor, potent functional activity in vitro, and good oral bioavailability in rats. The thiophene analog exhibited low iv clearance, long half-life, and high brain penetration. In obese rats, the thienopyridazinone demonstrated a dose-dependent reduction in feeding and body weight with doses between 1 and 10

mg kg⁻¹.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1170336 HCAPLUS

DOCUMENT NUMBER: 143:440267

TITLE: Preparation of aminopyrrolidinyl pyridines as MCH receptor antagonists

INVENTOR(S): Goodfellow, Val; Dyck, Brian P.;
Zhao, Liren; Tamiya, Junko; Grey,
Jonathan; Wade, Warren; Rowbottom, Martin
; Zhang, Mingzhu; Vickers, Troy D.

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103039	A1	20051103	WO 2005-US12853	20050415
WO 2005103039	C1	20060511		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005256124	A1	20051117	US 2005-107317	20050415
PRIORITY APPLN. INFO.:			US 2004-562389P	P 20040415
OTHER SOURCE(S):	MARPAT 143:440267			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, (un)substituted alkyl, aryl, etc.; R2 = H, C(O)R4, (un)substituted alkyl, etc. or R1 and R2 together may form (un)substituted heterocycle; R3 = H, CN, halo, etc.; R4 = OH, (un)substituted -O-alkyl, arylalkyl, etc.; Het = mono- or bicyclic (un)substituted heterocycle containing 1-3 heteroatoms selected from O, S or N and containing a keto functionality that is adjacent to the carbon which the pyridyl ring is attached to; X = a bond or O; Cyc = (un)substituted cycloalkyl, aryl or heterocycle] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of MCH receptor. Thus, e.g., II was prepared by reduction of 4-bromophthalimide followed by treatment with hydrazine to give the resp. bromophthalazinone, which underwent a palladium catalyzed Suzuki coupling with 4-(trifluoromethyl)phenylboronic acid and subsequent coupling with III (preparation given). Assay methods for

evaluation of binding ability of I to MCH receptors are described (no data). I as MCH receptor antagonist should prove useful in the treatment of obesity, depression and fertility dysfunction. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:636156 HCAPLUS

DOCUMENT NUMBER: 143:241362

TITLE: 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists

AUTHOR(S): Huang, Charles Q.; Baker, Tracy; Schwarz, David; Fan, Jun; Heise, Christopher E.; Zhang, Mingzhu; Goodfellow, Val S.; Markison, Stacy; Gogas, Kathleen R.; Chen, Takung; Wang, Xiao-Chuan; Zhu, Yun-Fei

CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, CA, 92130, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(16), 3701-3706

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Derivs. of 1-(4-amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine were identified as potent and functionally active MCH-R1 antagonists. One compound with $K_i = 2.3$ nM demonstrated good oral bioavailability (32%) and in vivo efficacy in rats.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:451389 HCAPLUS

DOCUMENT NUMBER: 143:7724

TITLE: A preparation of pyrimidine derivatives, useful as melanin-concentrating hormone receptor antagonists

INVENTOR(S): Goodfellow, Val; Zhang, Mingzhu; Tamiya, Junko

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005047293	A1	20050526	WO 2004-US37203	20041105
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

US 2005176738 A1 20050811 US 2004-982696 20041105
 PRIORITY APPLN. INFO.: US 2003-518480P P 20031107
 OTHER SOURCE(S): MARPAT 143:7724
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of pyrimidine derivs. of formula I [wherein: R1 is H, halogen, CN, alkyl, or arylalkyl, etc.; R2 is H, alkyl, aryl, or heterocycle, etc.; R3 is pyrrolidin-3-yl derivs.; X is CH or N; Y is S, O, or CH:N, etc.], useful as melanin-concentrating hormone (MCH) receptor antagonists (no biol. data). For instance, thienopyrimidine derivative II was prepared via amidation of carbamic acid derivative III by pyrrolidinylthienopyrimidine derivative IV, N-debenzylation, and N-alkylation by 4,4-dimethylcyclohexanone.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:780502 HCAPLUS

DOCUMENT NUMBER: 141:295848

TITLE: Preparation of bis(3-aminopyrrolidin-1-yl)methanones as melanin-concentrating hormone receptor antagonists for treatment of obesity and other disorders

INVENTOR(S): Goodfellow, Val; Rowbottom, Martin
 ; Dyck, Brian P.; Tamiya, Junko;
 Zhang, Mingzhu; Grey, Jonathan;
 Vickers, Troy; Kiankarimi, Mehrak; Wade,
 Warren; Hudson, Sarah Clough

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080411	A2	20040923	WO 2004-US7260	20040308
WO 2004080411	A3	20041216		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2004259931	A1	20041223	US 2004-797487	20040308
US 7067509	B2	20060627		
PRIORITY APPLN. INFO.:			US 2003-452709P	P 20030307
OTHER SOURCE(S):	MARPAT 141:295848			
GI				



AB Title pyrrolidinamines I [wherein $n = 0, 1$; $R1 = H$, (un)substituted (aryl)alkyl, heterocycl(alkyl); $R2 = H$, (un)substituted alkyl, COR7, SO2R8; or $NR1R2 =$ (un)substituted heterocycl(alkyl); $R3, R5, R6, R8 =$ independently H , (un)substituted alkyl; $R4 =$ (un)substituted alkyl, (hetero)aryl, heterocycl(alkyl); $R7 =$ independently H, OH , alkoxy, (un)substituted alkyl, aryl, heterocycl(alkyl); $R9 = OH$, alkoxy, (un)substituted alkyl, aryl; and stereoisomers, prodrugs, or pharmaceutically acceptable salts thereof] were prepared as melanin-concentrating hormone (MCH) receptor antagonists. For example, a 6-step synthesis starting from (R)-3-amino-1-benzylpyrrolidine, 4-nitrophenyl (S)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate, 4-trifluoromethyl-5-phenylthiophene-2-carboxylic acid, and cycloheptanone gave II. Over half of the exemplified invention compds., including II, exhibited the ability to bind to the human [125I]-MCH receptor with K_i values $<1 \mu M$. Thus, I and their pharmaceutical compns. are useful for the treatment of MCH receptor-based disorders, such as obesity, anxiety, depression, digestive disorders, fertility, sexual function disorders, and urinary disorders (no data).

=>